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ABSTRACT 
 
ZIAD MOUSTAFA ELETR: Deciphering and Modulating the Determinants of  
E2–HECT Binding and Specificity 
(Under the direction of Brian Kuhlman) 
 
The ubiquitin pathway regulates nearly all cellular processes in eukaryotes and consequently 
aberrations within the pathway can lead to a diversity of human diseases and disorders.  Ubiquitin is a 
76 residue protein that is conjugated to specific protein substrates via a cascade of enzymatic 
reactions that require an activating enzyme (E1), conjugating enzymes (E2s), and ligases (E3s).  In 
humans there is a single E1, roughly 30 E2s, and hundreds of E3s.  There are two main types of E3s 
that are structurally and functionally unrelated.  RING E3s catalyze the direct transfer of ubiquitin 
from E2 to substrate while HECT E3s form a thioester intermediate with ubiquitin prior to transfer.  
In most cases E2s function with many E3s while E3s function with one or few homologous E2s.  The 
study of diseases and disorders stemming from the ubiquitin pathway is complicated by the E1–E2–
E3 hierarchy and by elusive E3 substrates.  An attractive method to identify E3 substrates is to isolate 
specific E2–E3 interactions in the cell.  One means to isolate E2–E3 interactions is to create altered 
specificity E2–E3 pairs that function with each other but not their wild type precursors nor other 
natural partners.  The ability to create altered specificity E2–E3 pairs hinges on our understanding of 
the amino acid residues that dictate binding affinity and specificity.  The intent of the work in this 
dissertation is to identify these determinants of binding affinity and specificity and rationally 
manipulate them.  We have focused on the HECT class of E3s and began with the UbcH7–E6AP 
interaction as a model system.  We used a combination of quantitative binding assays, mutagenesis, 
and ubiquitin transfer assays as well as rational and computation protein engineering to elucidate and 
manipulate the amino acid residues that govern E2–HECT binding affinity and specificity.   
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 CHAPTER I 
INTRODUCTION TO THE UBIQUITIN PATHWAY
2 
EARLY HISTORY OF THE UBIQUITIN PATHWAY 
The ubiquitin protein was discovered by Goldstein and colleagues in 1975 and named so because it 
was thought to be ubiquitously present in all living cells1.  A few years later, a unique protein 
structure was observed when modified histone H2A protein was found to have two N-termini but just 
one C-terminus2.  This branched protein structure was generated by an isopeptide bond between the ε-
amino group of a histone H2A lysine and a glycine residue of the smaller polypeptide2 which was 
shortly thereafter identified as ubiquitin3.  The cellular role of protein modification by ubiquitin was 
largely discovered by Avram Hershko, his graduate student Aaron Ciechanover, and their 
collaborator Irwin Rose.  In studying ATP-dependent protein degradation, Hershko and Ciechanover 
were able to fractionate rabbit reticulocyte lysates into two components: fraction I which contained a 
small thermostable protein they called APF-1 (subsequently identified as ubiquitin4) was void of 
proteolytic activity, but when combined with fraction II and ATP was able to reconstitute 
proteolysis5.  Two years later in collaboration with Rose’s lab, it was shown that ubiquitin is 
conjugated to reticulocyte proteins when fractions I and II were combined with ATP, suggesting that 
ubiquitination is a pre-requisite for degradation.  Their results also suggested and that ubiquitin 
conjugation was likely carried out by an enzyme because conjugation activity was dependent on time 
and temperature6.  The following report by Hershko, Ciechanover, Rose and co-workers showed that 
multiple ubiquitin molecules are conjugated in a processive manner (poly-ubiquitination) and that 
depletion of ATP results in liberation of ubiquitin molecules7.  From this groundbreaking study, the 
authors predicted the activity of three components of the pathway; a factor promoting processive 
ubiquitin conjugation (E3 ligases), a factor with amidase activity (deubiquitinating enzymes), and a 
protease specific for ubiquitin conjugated proteins (26S proteasome)8.  In an effort to isolate all 
components necessary for ubiquitination activity, Hershko and Ciechanover soon thereafter 
discovered the E1, E2, and E3 enzymes9; 10.  In 2004, the Nobel Prize in Chemistry was awarded to 
Ciechanover, Hershko, and Rose for their pioneering work in the discovery of the ubiquitin pathway.  
3 
THE UBIQUITIN PATHWAY 
We now know that the ubiquitin pathway regulates virtually all cellular process in eukaryotes by 
targeting proteins for degradation by the 26S proteasome11.  A requirement for proteolysis via the 26S 
proteasome is a polymer of four or more ubiquitin molecules linked together via isopeptide bonds 
between the C-terminal glycine (G76) and lysine 48 (K48)12.  Ubiquitin has six other lysine residues 
(K6, K11, K27, K29, K33, and K63) all of which are capable of forming isopeptide linkages with 
G76 of a second ubiquitin molecule13.  Less is known about the cellular fate of such modifications, 
but G76–K63 ubiquitin polymers are thought to serve a non-proteolytic role14.  In addition, mono-
ubiquitination of cell membrane receptors can trigger their internalization and degradation in the 
lysosome15.  The hydrolysis of G76-mediated isopeptide bonds, or deubiquitination, adds an 
additional means to regulate the process of ubiquitination and is carried out by ~60 different proteins 
in humans16. 
The tethering of ubiquitin to itself and to proteins substrates is achieved by E1, E2, and E3 
enzymes.  The E1 activating enzyme uses ATP to adenylate the C-terminus of ubiquitin to form a 
reactive ubiquitin molecule.  Following adenylation, the E1 uses a cysteine residue to form a thioester 
intermediate with G76 of ubiquitin.  The E1 then binds to an E2 conjugating enzyme, transferring 
ubiquitin to the E2 active-site cysteine to form a second thioester intermediate.  E3 ligases are 
responsible for binding to E2 and substrate and these two binding events are carried out by distinct 
domains in a protein or by multiple proteins in a multisubunit E3 complex.  Catalysis can proceed in 
two mechanisms and is dependent on the type E2-binding domain.  Ubiquitin can be transferred 
directly from E2 to substrate (RING, PHD, and U-box E3s) or by first forming a third thioester with 
E3 prior to transfer to substrate (HECT E3s).  In humans there is a single E1, ~33 E2s, and hundreds 
of E3s.  Not all E2s and E3s can functionally interact.  In general E2s function with many E3s while 
E3s only function with one or few E2s11.  This E2–E3 specificity is important for maintaining proper 
spatial and temporal degradation of specific proteins.    
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Ubiquitin-like proteins (UBLs) share homology with the ubiquitin protein.  Like ubiquitin, UBLs 
are conjugated to lysine residues of a protein substrate using an E1–E2–E3 cascade. The roles of such 
modifications are diverse in function but do not lead to degradation.  UBL pathways have dedicated 
E1, E2, and E3 enzymes that in general do function in the ubiquitin pathway.  The best studied UBLs 
in humans are Nedd8, SUMO, and ISG1517.  The Nedd8 modification functions to upregulate the 
cullin family of E3 ligases by relieving inhibition imposed by the CAND1 protein18; 19 and/or by 
recruiting the E2s to E3 complex20; 21; 22.  The SUMO modification can serve various functions such as 
preventing ubiquitination and degradation, localization to nuclear pores, and upregulating protein 
activity23.  Though the SUMO pathway has dedicated E3s24, the SUMO E2 can directly bind and 
sumolyate substrates bearing the consensus sequence [I/V/L]-K-X-[D/E]17; 23.  The ISG15 UBL is 
likely involved in the innate immune response and recently a myriad of cellular proteins were shown 
to bear this modification upon stimulation with IFN-β25. 
5 
E2 CONJUGATING ENZYMES 
In humans there are ~33 E2 enzymes all of which share a conserved catalytic core domain of ~150 
amino acids.  Some E2s have N- and C-terminal extensions that confer these E2s with diverse 
functions.  For example the Nedd8 E2 Ubc12 possesses a unique N-terminal extension that is required 
for an optimal interaction with its cognate E126.  Roughly fifty structures of E2s have been deposited 
in the RCSB protein databank.  The E2 catalytic core domain is composed of a four-stranded β-sheet, 
four α-helices, and a 310 helix proceeding to the active-site cysteine.  The E2 catalytic core remains 
relatively unchanged when interacting with E1, E3s, and ubiquitin as evidenced from structures of 
E2s in complex with these proteins27; 28; 29; 30; 31.  These structures also suggested that the E1-binding 
and E3-binding sites of E2s partially overlap.  This is indeed the case as a series of competitive 
binding experiments showed that E1 and E3 compete for E2 and that a ternary E1–E2–E3 complex is 
not formed32. 
Crystal structures of the E2 UbcH7 in complex with a HECT E327 and a RING E328 revealed that 
E2s use similar residues to contact both types of E3s.  In both structures the primary interface contact 
was contributed by the loop 4-Phe63 side-chain of UbcH7 (L4-Phe) which buries into hydrophobic 
grooves created by the E3s.  Other contacts from UbcH7 were contributed from the N-terminal helix 
(H1), loop 4 (L4), loop 7 (L7) and to a lesser extent loop 2 (L2).  In our studies on E2–E6AP 
specificity, we found that an L4-Phe is necessary for interacting with E6AP and that mutation to 
alanine reduced binding by 3 kcal/mol33.  This L4-Phe can also be considered a primary specificity 
determinant as all E2s that have been shown to function with HECT E3s possess a phenylalanine at 
this position34.  Amino acids within H1 and L7 are more varied across E2s and thought to dictate the 
specificity of E2–HECT interactions27.  Sequence alignment and phylogenetic analysis of the 33 
human E2s shows that some share high sequence identity within and beyond the catalytic core 
(Appendix I).  Additionally, these E2s paralogs are highly conserved within the E3-binding positions 
suggesting that these E2s will display similar specificities for E3s.      
6 
HECT E3 UBIQUITIN LIGASES 
The first HECT domain characterized resided within the E6AP protein.  E6AP was initially 
identified as a protein that cooperates with the E6 protein from oncogenic forms of the human 
papillomavirus to destabilize cellular levels of the p53 tumor suppressor protein35.  The conserved 
HECT domain is ~350 amino acids and always found at the C-terminus of E3s.  Four crystal 
structures of HECT domains are now deposited in the RCSB protein databank27; 36; 37; 38.  The HECT 
domain adopts a bilobal structure with N-terminal lobe harboring the ~80 residue E2-binding 
subdomain and the C-terminal lobe containing the catalytic cysteine.  A three residue hinge connects 
the two lobes which interact to form a conserved interface27.  Superimposition of the E2-binding 
domain of the four HECT crystal structures reveals that the orientations of the two are markedly 
different in each structure.  Conformational flexibility of the HECT domain is known to be important 
for catalysis as mutations to the hinge and the interface of the two lobes have been shown to reduce 
ligase activity37; 39; 40.   
Different HECT E3s are capable of synthesizing different types of poly-ubiquitin chains (K48, 
K29, and K63) using distinct mechanisms suggesting additional roles for HECT E3s in non-
proteolytic regulation of proteins13; 41.  The residues N-terminal to the HECT domain are responsible 
for substrate interactions.  In humans there are at least 27 HECT E3s, of which nine are similar in 
their N-terminal domain architecture (Appendix II).  These E3s represent the C2-WW-HECT 
superfamily of E3s and contain an N-terminal C2 domain (phospholipid binding) followed by 2-4 
WW domains (poly-proline binding).  Within this C2-WW-HECT superfamily are four HECT 
subfamilies (HERCW, AIP, Smurf, and Nedd4).  These HECT paralogs share high identity 
throughout the C2, WW, and HECT domains.  Though the superfamily is similar in domain 
architecture, the four subfamilies have subtle amino acid differences in their HECT domains which 
results in dissimilar preferences for E2s.  For example the Nedd4 subfamily functionally interacts 
with the UBC4/5 E2s whereas the Smurf subfamily does not efficiently function with any E2s 38; 42; 43.  
To induce a functional E2 interaction, the Smurf2 protein must bind an additional protein Smad7 
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which specifically recruits UbcH7 to the HECT domain.  HECT E3s from the same subfamily share 
high sequence identity within their E2-binding residues suggesting they function with similar E2 
subfamilies.  Indeed this has been observed for the Nedd4 and Nedd4L proteins43.  
8 
UBIQUITIN AND DISEASE 
It is well established that various human diseases and disorders are consequences of E3s 
improperly regulating their substrates44; 45.  For example, inherited disorders such as Angelman’s 
syndrome, Liddle’s syndrome, and autosomal recessive Parkinson’s disease (AR-PD) have been 
linked to E3s with dysfunctional interactions with their substrates46; 47; 48; 49; 50.    In the case of 
Liddle’s syndrome, the HECT E3 Nedd4 no longer binds to or ubiquitinates the epithelial Na+ 
channel (ENaC) ultimately resulting in stabilization of ENaC, increased Na+ uptake and 
hypertension51; 52.  In approximately 75% of patients with Angelman’s syndrome, the maternal copy 
of the gene encoding the HECT E3 E6AP has been entirely deleted or has acquired mutations53 that 
have been shown to reduce ligase activity39; 40.  Though a handful of E6AP substrates have been 
identified35; 39; 54; 55; 56, none have been implicated in the pathogenesis of Angelman’s syndrome. 
Similarly, approximately 50% of patients with AR-PD have acquired mutations to the gene encoding 
a RING E3 Parkin57 but the link between Parkin substrates and the etiology of AR-PD remains 
unclear58; 59.  
In addition to inherited disorders, idiopathic diseases can arise from aberrant regulation of 
substrate ubiquitination. The pathology of sporadic neurodegenerative disorders like Parkinson’s 
disease and Alzheimer’s disease are partially the result of a dysfunctional ubiquitin pathway; the 
hallmark of these diseases is the accumulation of ubiquitinated proteins and inclusion bodies45.  
Cervical carcinomas caused by human papillomavirus (HPV) are a result of a viral protein E6 
hijacking E6AP to degrade the p53 tumor suppressor protein35.  Increased degradation of the cyclin 
dependent kinase inhibitor p27 has been linked to carcinomas of the colon, prostate, and breast60.  
Given the breadth of the ubiquitin pathway, it is not surprising that a plethora of malignancies arise 
from dysregulation within the pathway.  The identification of all the substrates of a given E3 would 
aid in the study and treatment of diseases stemming from the ubiquitin pathway
9 
TOWARDS A NEW METHOD OF IDENTIFYING E3 SUBSTRATES 
The identification of all the substrates of a given E3 is a challenging but very important task.  
Previous methods have relied on a variety of techniques including two-hybrid screens and 
coimmunoprecipitations.  Though both approaches have led to the identification of numerous E3 
substrates, both are inherently limited when applied to detecting E3–substrate interactions.  The two-
hybrid screen is usually performed in a host system so E3 substrates that require phosphorylation or 
other post-translational modifications prior to recognition by E3 may not bind E3 with sufficient 
affinity for detection.  Coimmunoprecipitations are limited by the stability of the ubiquitinated 
substrate as deubiquitinating enzymes and the 26S proteasome function to remove ubiquitin and 
degraded the substrate.  Inhibitors of the proteasome and deubiquitinating enzymes can be useful but 
again the context of the interaction has been altered.  Clearly a better approach is needed.  An ideal 
method would allow for the detection of low affinity E3–substrate interactions without significantly 
perturbing the cellular environment. One way to craft such a tool is by creating altered specificity E2–
E3 pairs.  Altered specificity pairs would allow a specific E2–E3 interaction to be isolated in the cell 
so that downstream events can be examined.   
The manipulation of an E2–E3 pair has been demonstrated previously61.  A charge swap interaction 
was generated across the UbcH5b-CNOT4 interface to create a mutant pair that no longer interacted 
with the WT precursors61.  In this study the authors claim to have generated an altered specificity pair 
but the mutant proteins were not tested against other natural partners.  A bona fide altered specificity 
E2–E3 pair must display two characteristics.  First, the redesigned E2 and E3 proteins must interact 
favorably with one another but not with their wild-type precursors.  Redesigned E2–E3 pairs 
displaying this property will be referred to as orthogonal E2–E3 pairs.  Second, the redesigned E2–E3 
pair should no longer interact favorably with other naturally occurring partners.  This property is most 
important for E2s because each E2 usually interacts with multiple E3s.  Since hundreds of proteins 
are ubiquitinated in the cell, the substrates of a specific E2–E3 pairs may remain difficult to detect.  
To circumvent this obstacle, instead of altered specificity pairs passing ubiquitin they could be 
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engineered to pass the UBL Nedd8 which has ~10 known substrates.  To achieve a method like this, 
the following challenges must be resolved.  (1)  All the natural E2–E3 pairs that yield functional 
interactions must be identified.  (2)  A method to generate orthogonal E2–E3 pairs must be 
developed.  Furthermore, orthogonal E2–E3 pairs must be screened against natural partners to test 
whether they are bona fide altered specificity pairs.  (3)  Engineered E2s must be able to bind to the 
Nedd8 E1 and form a Nedd8-E2 thioester intermediate.  (4)  The Nedd8-charged E2 must be able to 
pass Nedd8 to E3 and/or substrate.  (5)  A method to express altered specificity E2–E3 pairs in the 
cell must be developed.  (6)  Finally a method to detect and identify Nedd8-modified proteins must be 
developed.  The work in this dissertation has focused on challenges (1) and (2).  To simply matters 
we have chosen to restrict our characterization and engineering of E2–E3 interactions to the HECT 
family of E3 enzymes. 
11 
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ABSTRACT 
The conjugation of ubiquitin to substrates requires a series of enzymatic reactions consisting of an 
activating enzyme (E1), conjugating enzymes (E2) and ligases (E3).  Tagging the appropriate 
substrate with ubiquitin is achieved by specific E2–E3 and E3–substrate interactions.  E6AP, a 
member of the HECT family of E3s, has been previously shown to bind and function with the E2s 
UbcH7 and UbcH8.  To decipher the sequence determinants of this specificity we have developed a 
quantitative E2–E3 binding assay based on fluorescence polarization and used this assay to measure 
the affinity of wild-type and mutant E2–E6AP interactions.  Alanine scanning of the E6AP–UbcH7 
binding interface identified four side-chains on UbcH7 and six side-chains on E6AP that contribute 
more than 1 kcal /mol to the binding free energy.  Two of the hot spot residues from UbcH7 (K96 and 
K100) are conserved in UbcH8 but vary across other E2s.  To determine if these are key specificity 
determining residues, we attempted to induce a tighter association between the E2 UbcH5b and E6AP 
by mutating the corresponding positions in UbcH5b to lysine residues.  Surprisingly, the mutations 
had little effect, but rather a mutation at UbcH7 position 4, which is not at a hot spot on the UbcH7–
E6AP interface, significantly strengthened UbcH5bs affinity for E6AP.   This result indicates that 
E2–E3 binding specificities are a function of both favorable interactions that promote binding, and 
unfavorable interactions that prevent binding with unwanted partners.    
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INTRODUCTION 
Protein ubiquitination is an essential eukaryotic pathway that influences nearly all cellular 
processes1.  The conjugation of ubiquitin to a protein substrate requires a cascade of enzymatic 
reactions beginning with the ubiquitin activating enzyme (E1).  The E1 uses ATP to form a thioester 
bond between the carboxyl terminus of ubiquitin and the E1 active site cysteine.  The E1 then binds a 
ubiquitin conjugating enzyme (E2) and transfers ubiquitin to the E2 active site cysteine.  The next 
step in the pathway requires a ubiquitin ligase (E3) which utilizes distinct domains to bind both E2 
and substrate.  The two major classes of E3s bind E2s using either a RING (really interesting gene) 
domain or a HECT (homology to E6AP carboxy terminus) domain.  E3s containing a HECT domain 
form a third thioester intermediate with ubiquitin prior to transfer to substrate2.  E3s that contain a 
RING domain do not form a covalent intermediate with ubiquitin, but rather bring the substrate in 
proximity of the E2 whereby transfer of ubiquitin proceeds directly from E2 to substrate. 
The importance of specific E3–substrate interactions is apparent as aberrations can lead to 
improper substrate regulation and severe physiological consequences3; 4.  Often overlooked is the 
specificity of E2–E3 interactions as similar outcomes could potentially arise.  The hierarchical nature 
of the ubiquitin pathway presents a formidable task in dissecting all E2–E3 and E3–substrate 
interactions.  For example in humans there is a single E1, ~30 E2s and hundreds of potential E3s.  In 
general, a given E2 will interact with multiple E3s while E3s only function with a limited subset of 
E2s4.  Additionally, a given E3 may have more than one substrate and some substrates can be 
recognized by multiple E3s4.  One possible method to dissect the network of interactions is to design 
altered specificity E2-E3 pairs that will function together but not with their wild-type partners.  Such 
an approach has been taken by Marc Timmers and colleagues who used a charge swap interaction 
across the UbcH5b–cNOT4 interface to create an altered specificity E2-RING pair5.  The Timmers 
study, as well as others, have helped map the determinants of E2-RING specificity5; 6; 7; 8; 9.  Here, we 
examine the sequence determinants of E2-HECT specificity.  In particular, we focus on the HECT 
domain protein, E6AP.     
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E6AP is the founding member of the HECT domain class of E3s.  It was first identified as a 
protein that cooperates with the E6 protein from oncogenic forms of the human papillomavirus to 
down regulate the p53 tumor suppressor10.  The conserved ~350 amino acid residue HECT domain 
adopts a bilobal structure and is always found at the C-terminus of E3s.  A three residue hinge 
connects the N-terminal E2 binding lobe with the catalytic C-terminal lobe and the interface created 
by the two lobes forms a highly conserved cleft containing the catalytic cysteine11 (Figure 2.1(a)).  
Three crystal structures of HECT domains have revealed significantly different orientations of the 
two lobes, implying that conformational changes are necessary for catalysis11; 12; 13.  Hinge mutations 
to proline that restrict the conformational flexibility of the HECT domain result in impaired E3 
activity12.  Also, some patients with Angelman syndrome (AS), a severe neurological disorder linked 
to E6AP, have acquired mutations within the conserved cleft that have been shown to reduce E6AP 
ligase activity14; 15.  Despite the significant progress on AS associated E6AP mutations, none of the 
identified E6AP substrates have been directly linked to the disorder16.  A better understanding of 
HECT domains as well as their E2s and substrates may help combat such E3 associated diseases. 
All E2 enzymes possess a conserved catalytic core domain of approximately 150 amino acid 
residues though some E2s also contain N- and C-terminal extensions which serve diverse functions16.  
The E2 core domain contains the residues responsible for catalysis as well as binding E1 and E3s.  
Crystal structures of the E2 UbcH7 bound to a HECT E3, E6AP11, and a RING E3, c-Cbl17, revealed 
that E2s utilize similar residues to bind both classes of E3s.  The majority of E3 binding residues are 
contained within the N-terminal helix (helix 1) as well as loops 4 and 7 11; 17 (Figure 2.1(b)).  In both 
E2-E3 structures, the primary contact at the interface arises from F63 on loop 4 of UbcH7 which is 
buried in a hydrophobic groove created by the E311; 17.  This phenylalanine is present in all E2s that 
have been shown to function with HECT E3s11; 18.  The sequences of helix 1 and loop 7 of HECT 
binding E2s are more varied, and it has been proposed that these regions of the interface determine 
which HECT domains an E2 will bind11.  HECT E3s have been shown to form selective interactions 
with at least three distinct E2 subfamilies19; 20; 21; 22.  To decipher the sequence determinants of E2-
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E6AP specificity, we have performed a variety of mutagenesis experiments to map out which E2 and 
E6AP residues are important for E2-E6AP affinity, and have used this information along with 
multiple sequence alignments to rationally perturb E2-E6AP binding preferences. 
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RESULTS 
E6AP selectivity for UbcH7 and UbcH8 
Previous two-hybrid studies and activity assays indicate that E6AP binds and functions with the 
E2s UbcH7 and UbcH8, and to a lesser extent UbcH5a19; 20.  To more precisely quantify these 
preferences and test a larger set of E2s, we measured the binding affinity of E6AP for nine E2s using 
a fluorescence polarization (FP) assay that we previously used to measure UbcH7-E6AP binding23.  
E2s were selectively labeled at cysteine side-chains using a thiol-reactive bodipy dye, and 
fluorescence polarization of the modified E2 was monitored as a function of E3 concentration.  To 
ensure that the bodipy labeling of the E2s was not influencing binding, we measured the binding 
affinity of unmodified UbcH7 for E6AP using isothermal titration calorimetry (ITC) 
(Supplementary Data, Figure 2.8).  The two experiments yielded similar measures of the UbcH7-
E6AP dissociation constant (KD of 5.0 µM from FP and 2.2 µM from ITC).  Of the E2s tested only 
UbcH8 contained a cysteine near the HECT-binding interface and for this reason we used a C97S 
UbcH8 mutant in our FP assays. 
Four of the E2s (Ubc9, UbcH10, Rad6b, and Ubc12) lack a phenylalanine at position 63 (F63) and 
were not expected to bind E6AP (Figure 2.2(a)).  The E2s with a F63 represent three distinct E2 
subfamilies according to a recent phylogenetic analysis of E2 enzymes24. Representatives of the 
UBC4/5 subfamily include yeast UBC4 and its human homolog UbcH5b (UbcH5a paralog).  The 
human UbcH2 protein belongs to the UBC8 subfamily while human UbcH7 and UbcH8 represent the 
UbcH7/8 subfamily.  The binding assays show that only UbcH7 and UbcH8(C97S) bind to E6AP 
with low micromolar affinity (Figure 2.2(b)).  The other E2s with a phenylalanine at position 63 
(UBC4, UbcH5b, and UbcH2) bind E6AP with affinities less than 200 µM.    Of the E2s lacking F63, 
UbcH10, Rad6b, and Ubc12 did not bind E6AP.  Ubc9, the SUMO-conjugating enzyme, was able to 
weakly interact with E6AP.  These results are consistent with previous findings that show that HECT 
E3s preferentially interact with E2s containing a phenylalanine at position 6311; 18. 
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Identifying hot spot residues at the UbcH7–E6AP interface 
Having confirmed the importance of F63 to binding E6AP, we next set out to identify secondary 
determinants that provide E6AP selectivity for the UbcH7/8 subfamily.  We used alanine scanning of 
the E6AP–UbcH7 interface followed by binding measurements to determine which side-chains 
contribute most to binding.  A total of 36 residues at the interface were mutated to either alanine or 
glycine.  The mutants were expressed in Escherichia coli and binding affinities were measured with 
the FP binding assay.  
The free energy of binding for the wild-type UbcH7–E6AP interaction was measured at 7.2 
kcal/mol (KD = 5.0 µM).  As expected, the mutation resulting in the largest loss of binding energy was 
F63A (∆∆G°bind = 3.0 kcal/mol).  None of the other mutants tested lost more than 2 kcal/mol, but nine 
mutants lost greater than 1 kcal/mol.  Together with F63 these residues will be referred to as hot spots 
(Table 2.1).  Of these nine mutants, four are hydrophobic E6AP residues (L635A, L639A, L642A, 
and F690A) that form van der Waals contacts with F63 (Figure 2.3).  An unexpected finding was that 
two UbcH7 loop 7 lysine residues, K96 and K100, were binding hot spots.  In the crystal structure, 
K96 forms a salt bridge with D641 of E6AP while the K100 hydrogen bonds with the D652 backbone 
carbonyl of E6AP.  Hot spots were also observed at a completely conserved proline preceding F63 as 
well as M653 and Y645 of E6AP.  The latter two residues form van der Waals contacts with P97 and 
A98 of UbcH7 loop 7.  Of the remaining mutants we found 16 to be moderately destabilizing 
(∆∆G°bind of 0.25 to 1.0 kcal/mol).  These residues are a mixture of polar, charged, and hydrophobic 
amino acids.  Interestingly these residues form a shell around the hydrophobic hot spot residues of 
UbcH7 and E6AP (Figure 2.3).  Like the reciprocating hydrophobic hot spots, moderately 
destabilizing residues of UbcH7 interact with moderately destabilizing residues of E6AP.  The final 
ten mutants exhibited either neutral (∆∆G°bind of –0.25 to 0.25 kcal/mol) or stabilizing (∆∆G°bind < –
0.25 kcal/mol) effects on the binding free energy.  These residues cluster further from the hot spots 
and outside the shell of moderately destabilizing residues (Figure 2.3).  The observed pattern of an 
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energetically important hydrophobic interface core surrounded by a shell of energetically less 
important residues is not uncommon to protein–protein interfaces25; 26.   
Other mutations were made to UbcH7 and E6AP to serve as controls.  In the UbcH7–E6AP crystal 
structure, R52 of UbcH7 is solvent exposed and situated opposite the binding interface.  Mutation of 
this residue to alanine resulted in wild-type binding affinity (Table 2.1).  Similarly, no change in 
binding free energy was observed upon mutating the E6AP catalytic cysteine to alanine (C820A) 
(Table 2.1).  Previous studies on the WWP1 HECT domain found that a double proline mutation in 
the hinge connecting the N and C lobes resulted in reduced ligase activity12.  To confirm that the 
impaired activity arises from restricted conformational flexibility and not perturbed binding, the 
analogous positions in E6AP were mutated to proline (S739P N741P).  The resulting mutant bound 
UbcH7 with wild-type affinity (Table 2.1). 
 
Charge swap mutations at the UbcH7–E6AP interface 
To identify charged amino acids engaged in electrostatic interactions across the interface we 
measured binding affinities of ten UbcH7–E6AP charge swap mutants (Table 2.1).  The binding 
affinities from the charge swap experiments were grouped into the same categories as the alanine 
mutant affinities.  Six of the mutants lost > 1.0 kcal/mol of binding free energy.  These include 
UbcH7 helix 1 mutants R5E, R6E, and K9E as well as loop 7 charge swaps K96E and K100E.  The 
helix 1 mutants form inter-chain (R5 and R6) and intra-chain (K9) hydrogen bonds to backbone 
oxygen atoms.  The D652R mutation was also largely destabilizing, possibly because of a loss of 
interaction with K100.  Three of the remaining charge swap mutants displayed less significant losses 
in binding energy (E60R, K64E, and D641K).  The E93R mutant displayed a large gain in binding 
energy that may be the result of a new hydrogen bond with the Q637 E6AP side-chain. 
Only two side-chain–side-chain charged interactions are present across the interface, K100–D652 
and K96–D641. We proceeded to test the mutant pairs for an altered specificity interaction.  The 
effects from K100E–D652R interaction were as unfavorable as the effects of either single mutant 
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(∆∆Gbind of 1.6 kcal/mol).  In contrast, the K96E–D641K mutant pair displayed a charge swap 
interaction that was more favorable than the wild-type interaction (∆∆Gbind of –0.8 kcal/mol). For the 
purpose of creating an altered specificity UbcH7–E6AP pair, the K96–D641K mutant pair would only 
achieve specificity towards E3s because the D641K mutant displays no defects in binding wild-type 
UbcH7.  A sub-optimal K96–D641K salt-bridge in the wild-type interaction could give rise to such 
results.  These findings suggest that creating an altered specificity UbcH7–E6AP pair using a charge 
swap interaction may prove difficult.   
 
Ubiquitin transfer rates correlate with UbcH7–E6AP binding affinity 
Ubiquitin transfer assays were used to assess if changes in UbcH7–E6AP binding affinity 
influence the rate ubiquitin is transferred to E6AP.  Activity assays were not performed with mutant 
UbcH7 proteins because of potential complications from altered E1-UbcH7 activity.  All E6AP 
mutants were tested in reactions containing radiolabeled ubiquitin, E1, UbcH7, ATP and an ATP 
regenerating system.  Each reaction was quenched in SDS-PAGE loading buffer lacking β-
mercaptoethanol (β-ME), separated by SDS-PAGE, and ubiquitin-modified proteins were visualized 
using a phosphorimager (Figure 2.4(a)).  Ubiquitin-modified E6AP appears as two bands and UbcH7 
as a single band.  The wild-type reaction quenched in loading buffer containing β-ME demonstrates 
that the ubiquitin modifications to both UbcH7 and the faster migrating E6AP band are mediated via 
thioester linkages (denoted with ~).  The slower migrating E6AP band that is resistant to treatment 
with β-ME likely represents ubiquitin modification via an isopeptide bond (denoted with –).  No 
ubiquitin-modified E6AP is observed in reactions using the catalytic cysteine mutant (C820A) or the 
control lacking E6AP. 
Phosphorimaging software was used to quantify the total amount of Ub~E6AP formed in each 
reaction as well as the amount of Ub~UbcH7 (Figure 4(b)).  Ub-UbcH7 levels were not constant 
between the various reactions, indicating that the rates of Ub~E6AP formation were partially limited 
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by the E1/UbcH7 reaction rates.   Indeed, in reactions with the tighter binding E2–E3 pairs the 
Ub~UbcH7 band was very weak, suggesting that the rate of Ub~E6AP formation depended almost 
entirely on the E1/UbcH7 reaction rate.  Previously, we have shown that E3 and E1 binding to UbcH7 
are mutually exclusive and that saturating amounts of E3 can inhibit the E1/E2 transfer step23.  We do 
not believe that is occurring in this case as the E3 concentrations are well below saturating levels.  
Despite being partially limited by the E1/E2 transfer step, there is still a correlation between the 
amount of Ub~E6AP formed and the E2/E3 binding affinities (correlation coefficient = 0.58).  E6AP 
hot spot mutants Y645A, D652R, F690A, and M653A as well as Y694L, M654A, and S739P N741P 
formed less than 55% of the ubiquitin-E6AP observed in the wild-type reactions.  All the E6AP 
mutants displaying enhanced binding affinity resulted in an increase in the formation of ubiquitin-
E6AP.   There are a few outliers.  L639A and L635A weaken binding by > 1 kcal/mol, but do not 
show a reduced amount of Ub~E6AP formed.  However, there is a greater build up of Ub~UbcH7 for 
these two reactions than for the wild-type reaction.  Overall, the results indicate that E2/E3 binding 
affinity does affect E2/E3 ubiquitin transfer rates, but that there could be additional important factors 
such as on and off rates, rate of transfer within the bound complex and the affinity of ubiquitin 
charged E2 for the E3.    
 
UbcH7–E6AP hot spots are essentially conserved in the UbcH8–E6AP interaction 
The hot spot residues in UbcH7, F63, K96 and K100, are conserved in UbcH8 (F62, K95 and 
K99).  To confirm that these residues are playing the same role at the UbcH8–E6AP interface we 
mutated them to alanine and measured affinity for E6AP.  The UbcH8 F62A mutation abolished 
binding to E6AP.  The K95A and K99A mutations proved to be destabilizing with losses in binding 
energy of 0.9 and 1.3 kcal/mol respectively (Table 2.2).  In both E2s, the double loop 7 mutants show 
nearly additive effects from the single mutants, but still the combined destabilization is less than the 
loop 4 phenylalanine mutation.   We also tested our panel of E6AP mutants with UbcH8 in binding 
assays.  There is a striking similarity in the binding affinities of UbcH7 and UbcH8 for E6AP mutants 
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(Figure 5).  Only two significant discrepancies are observed and these are L639A and D641K; both 
are stabilizing with UbcH8 yet destabilizing with UbcH7.  These results show that hot spots at the 
UbcH7–E6AP interface are also hot spots at the UbcH8–E6AP interface.   
 
Redesigning UbcH5b to bind E6AP 
To further explore the determinants of E2-E6AP binding specificity we characterized a set of 
mutations that were rationally designed to induce UbcH5b to bind more tightly to E6AP.  Our first 
design strategy was to mutate residues in UbcH5b that map to hot spot positions in UbcH7.  We made 
the S94K and T98K single and double mutants in UbcH5b and measured binding to E6AP (Figure 
2.6).  The S94K mutant destabilized binding by 0.5 kcal/mol while the T98K strengthened binding by 
0.4 kcal/mol.  The double mutant bound weaker than wild-type UbcH5b but stronger than the S94K 
single mutant.  A possible explanation for this result is that the extra residue present in UbcH7/8 loop 
7 (Figure 2.2(a)) may lead to different loop 7–E6AP interactions in UbcH5b.  From these results it is 
clear that conserving the hot spot residues from UbcH7 is not sufficient to induce low micromolar 
binding with E6AP.   
To further search for UbcH5b mutations that could increase affinity for E6AP we examined the E2 
multiple sequence alignment for residues that were not conserved between UbcH7 and UbcH5b but 
were located at the E6AP–UbcH7 interface.  The only residue that differs between the proteins and 
had an affect on UbcH7–E6AP affinity is serine 4 on UbcH7, which is a leucine in UbcH5b.  
Somewhat surprisingly, mutating this leucine on UbcH5b to serine (L3S) resulted in a significant gain 
of 1.2 kcal/mol in binding energy (KD of 23 µM) (Figure 2.6).  This mutation was tested in 
conjunction with the S94K and T98K mutants mentioned above, and the L3S T98K double mutant 
bound E6AP with UbcH7/8-like affinity.  So although the serine at residue 4 in UbcH7 is not making 
strong favorable interactions with E6AP, the residue located at this position can have a significant 
impact on E2-E6AP binding specificity.  The leucine at this position in UbcH5b is dictating 
specificity by disfavoring interactions with E6AP.
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DISCUSSION 
The sequence determinants of E2–E6AP binding affinity and specificity have been studied by 
mutational analysis.  The major findings can be summarized as follows.  (1) A F63 in loop 4 of an E2 
is necessary but not sufficient for tight E2–E6AP binding affinity as the five E2s that were 
characterized with this phenylalanine bind with affinities ranging from 5–180 µM.  Of these E2s only 
UbcH7 and UbcH8 bind E6AP with low micromolar affinity. (2)  In addition to F63, three side-chains 
on UbcH7 contribute > 1 kcal/mol to the binding free energy between UbcH7 and E6AP.  Two of 
these (K96 and K100) are located on the periphery of the interface and are not conserved in other E2 
subfamilies that bind more weakly to E6AP.  (3) The E6AP side-chains that contribute most to 
binding UbcH7 are hydrophobic and surround the F63 binding cleft.  (4) Residues that are not hot 
spots for the UbcH7–E6AP interaction can contribute significantly to E2–E6AP binding specificity.  
Mutating L3 of UbcH5b to a serine led to a ~tenfold increase in UbcH5b–E6AP affinity.       
An important question that remains is whether the interactions that determine E6AP-E2 specificity 
will translate to other E2-HECT interfaces.  Much of the initial work on E2-HECT specificity focused 
on E6AP and Saccharomyces cerevisiae Rsp5.  Different techniques yielded conflicting results as to 
which E2s these E3s preferred.  Studies using the yeast two-hybrid method showed that E6AP 
selectively interacts with UbcH7 and UbcH8 while Rsp5 prefers UbcH5a and UbcH620.  Other results 
using substrate or E3 ubiquitination assays show that UbcH5a and UbcH7 support equal E6AP 
activity or that Rsp5 is not active with UbcH618; 19; 22.  One consistent finding was that Rsp5 prefers 
UbcH5a.  Many human HECT E3s are closely related to yeast Rsp5 in their HECT domain as well as 
N-terminal substrate binding domains (Nedd4, Nedd4L, Smurf1/2, WWP1/2 and AIP4 in humans)27.  
A sequence alignment of the E2 binding region of HECT E3s (Figure 2.7) shows that within the 
Rsp5 subfamily there are conserved residues not present in E6AP.  Some of these differences map to 
a loop that is one to three residues shorter than E6AP in the Rsp5 subfamily.  In more structurally 
defined positions notable differences are observed at E6AP residues D641 (W in Rsp5 subfamily), 
V634 (D/E), and Y645 (N), and F690 (Y).  In an attempt to optimize the UbcH7–Smurf2 interaction, 
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Ogunjimi et al. found two mutations to Smurf2 that were capable of enhancing catalytic activity in 
vitro and in vivo13.   These mutations, H547I and Y581F, replaced polar groups in the binding groove 
with hydrophobic residues observed in E6AP (I655 and F690).  Other Rsp5 family members maintain 
the hydrophobic nature of I655.  Whether subtle differences within other Rsp5 family members will 
drive specificity towards the UBC4/5 family or towards other E2 families with an F63 remains 
undetermined.  Our results show that a subtle difference between UbcH7 and UbcH5b indeed affects 
binding to E6AP.  
Our in vitro ubiquitination assays with E6AP mutants demonstrate that E2–E3 affinity influences 
the rate ubiquitin~HECT thioesters can be formed.  In vivo there will be the added complexity that a 
variety of E3s will be competing for E2 binding sites, which could make E3 conjugation rates more 
sensitive to E2–E3 affinity.   Additionally, the study by Ogunjimi et al. found that an auxiliary protein 
Smad7 was able to bind both UbcH7 and the Smurf2 E3 via its WW domain and effectively enhance 
the activity of Smurf213. This finding suggests that in some cases the specificity of E2–E3 interactions 
may reside in a tertiary protein.  Discovering which E2–E3 pairs functionally interact in the cell is a 
challenging problem.  Introducing E2s and E3s with redesigned binding specificities into the cell may 
provide one route for deciphering the importance of specific interactions.  Our study (and others like 
it) on the determinants of E2–E3 specificity lays the foundation for such efforts. 
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FIGURES 
 
 
 
 
 
Figure 2.1. Cartoon representation of the UbcH7–E6AP crystal structure11. (a) The E6AP N-terminal 
lobe (blue) and C-terminal lobe (cyan) are connected by a three residue hinge (red). E6AP uses an 
~80 amino acid residue subdomain in the N-terminal lobe to bind UbcH7 (green). Catalytic cysteine 
side-chains of UbcH7 and E6AP are shown as van der Waals radii. (b) Close up of the UbcH7–E6AP 
interface. The most significant contacts arise from UbcH7 helix 1 (H1) as well as loops 4 and 7 (L4 
and L7), which interact with E6AP helices 7 and 8 (H7 and H8) and the H7-S5 loop. The Figure was 
generated using PDB 1C4Z11 and PYMOL [http://www.pymol.org]. 
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Figure 2.2. E6AP selectively interacts with UbcH7 and UbcH8. (a) Sequence alignment of the E3 
binding regions of a subset of E2 enzymes. The dots indicate UbcH7 residues used to bind E6AP and 
are colored by the change in UbcH7–E6AP binding energy associated with mutating the side-chain to 
alanine (or glycine) according to Figure 3. (b) Fluorescence polarization binding assays of E6AP 
(HECT) with each of the E2s listed in (a). The results show that only UbcH7 and UbcH8 interact with 
low micromolar affinity and that UBC4 and UbcH5b of the closely related UBC4/5 subfamily bind 
E6AP significantly weaker. Aside from UbcH7 and UbcH8, all E2s have sub-optimal amino acids at 
hot spots for E6AP. 
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Figure 2.3. Mapping ∆∆G°bind from alanine scan studies onto the UbcH7–E6AP structure. The 
interface view was obtained by rotating UbcH7 180° about the y-axis. Individual amino acid residues 
are colored by the change in binding free energy observed upon making the indicated mutation. F63 
of UbcH7 is the most important residue for binding. Other hot spots include E6AP residues lining the 
hydrophobic groove that contacts F63 as well as K96 and K100 of UbcH7. Residues with smaller 
contributions to binding form a shell around F63 and the hydrophobic E6AP groove. The Figure was 
generated using PDB 1C4Z11 and PYMOL. 
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Figure 2.4. In vitro activity of E6AP mutant proteins. (a) A ubiquitin transfer assay was used to 
detect the formation of ubiquitin-E6AP thioester in reactions containing 5 µM [32P]ubiquitin, 50 nM 
E1, 1 µM wild-type UbcH7 and 1 µM wild-type or mutant E6AP and an ATP regenerating buffer. 
The ubiquitin-E6AP thioester (Ub~E6AP) is reduced in the control reaction quenched in β-ME while 
the isopeptide-linked ubiquitin (Ub–E6AP) is retained. (b) For each reaction the total ubiquitin-E6AP 
formed was quantified and normalized to the wild-type reaction. The assay was repeated 
(Supplementary Data, Figure 2.9) and the averaged counts for each mutant is plotted versus the 
experimentally determined ∆∆G°bind. Error bars represent standard deviation of relative ub-E6AP 
formed and the standard error of ∆∆G°bind. 
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Figure 2.5. UbcH7 and UbcH8 form nearly identical interactions with E6AP. Bar graph comparing 
the observed change in binding free energy of E6AP mutants for UbcH7 and UbcH8(C97S). Nearly 
all E6AP interface residues contribute similar energy to binding UbcH7 and UbcH8(C97S). The two 
significant differences (L639A and the charge swap D641K) may arise from a slight difference in 
loop L7 of UbcH7 and UbcH8. The F690A mutant was not tested with UbcH8. 
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Figure 2.6. Rationally manipulating UbcH5b to enhance binding to E6AP. Three UbcH5b positions 
were mutated and tested for their contribution to binding E6AP. UbcH5b mutants containing the 
UbcH7 hot spot lysine(s) (S94K and T98K) alone were not able to significantly enhance binding. The 
L3 UbcH5b residue is a serine in UBC4, UbcH7 and UbcH8, and the L3S mutation resulted in a large 
increase in binding affinity for E6AP. The L3S T98K double mutant was capable of binding E6AP 
with UbcH7/8-like affinity. Interestingly the S94K mutation is destabilizing except when present with 
the L3S mutation. 
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Figure 2.7. Multiple sequence alignment of the E2-binding subdomain of Rsp5 family members and 
E6AP. The dots are colored by the change in UbcH7–E6AP binding energy associated with mutating 
the E6AP side-chain to alanine according to Figure 2.3. Amino acids lining the hydrophobic groove 
that interacts with F63 of E2s are generally hydrophobic and/or aromatic in the Rsp5 family of E3s. 
The Rsp5 family members have a one to three residue deletion in the H7-S5 loop and numerous non-
conservative substitutions at E6AP residues. Both of these differences likely play a role in dictating 
E2-HECT specificity. 
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MATERIALS AND METHODS 
Protein purification 
UbcH7, ubiquitin, and E6AP expression plasmids have been described23.  All other clones were 
obtained in or subcloned into pGEX vectors with N-terminal GST-tags followed by a thrombin 
recognition sequence.  Vectors harboring S. cerevisiae UBC4 and human UbcH5b, UbcH8, UbcH10, 
Rad6b, and UbcH2 were kindly provided by Marc Timmers.  Human Ubc12 and Ubc9 were kindly 
provided by Brenda Schulman and Jon Huibgretse respectively.  Point mutations were introduced 
using the QuickChange® site-directed mutagenesis protocol (Stratagene). All vectors were verified 
by DNA sequencing. 
Proteins were expressed overnight at 25˚ C with 0.3 mM IPTG in the BL21(DE3) strain of E. coli.  
Cells were disrupted by sonication and the resulting lysates were cleared by ultracentrifugation.  
UbcH7 was purified by metal chelating Sepharose followed by cation exchange and gel filtration.  
Ubiquitin was purified by metal chelating Sepharose followed by thrombin cleavage and gel 
filtration.  The HECT domain of E6AP and all other E2s were purified by glutathione Sepharose 
followed by thrombin cleavage, anion exchange and gel filtration.  For the Y694A E6AP mutant we 
were not able to purify a sufficient amount of protein, so instead we tested the Y694L mutation.  
Proteins were concentrated using Centricon® and Centriprep® centrifugal concentrators.  Extinction 
coefficients used to determine protein concentrations were calculated using the method described by 
Gill and von Hipple28. 
 
Isothermal titration calorimetry binding assay 
A Microcal-VP-ITC was used to measure the binding thermodynamics of unmodified UbcH7 for 
E6AP (Supplementary Data, Figure 2.8).  The experiment was performed at 25° C using 700 µM 
UbcH7 in the sample syringe and 1.45 ml of 35 µM E6AP in the sample cell.  A total of 41 5 µl 
injections of UbcH7 were performed at 5 min intervals.  The heat of dilution of UbcH7 was 
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calculated as the average of the final three titrations and this value was subtracted from the dataset.  
Origin software was used to fit the data to a single-site binding model and determine the 
stoichiometry (N) and thermodynamic parameters of binding ∆Hbind, ∆Gbind and ∆Sbind. 
 
Fluorescence polarization binding assays 
Binding assays, data analysis, and labeling of the E2 enzymes with bodipy (507/545)-
iodoacetamide (Molecular Probes) has been described23.  Starting concentrations for bodipy-E2 
depended on the extent of conjugated fluorophore and typically fell in the range of 0.5–2.0 µM.  
Manual titrations were performed using wild-type and mutant E6AP(HECT) stock solutions that 
varied based on yield and strength of the interaction.  All binding assays were performed at room 
temperature in 20 mM KH2PO4 (pH 7.0), 150 mM NaCl, 5 mM β-ME.  For each binding experiment, 
nine polarization readings were collected and averaged at 20 concentrations of E6AP(HECT).  Data 
were fit to a single-site binding model using non-linear regression with SigmaPlot software to yield 
parameters for Pmin (starting polarization), Pmax (maximum polarization), and KD (dissociation 
constant). 
 
In vitro ubiquitin transfer assay 
Isotopic labeling of ubiquitin with 32P was carried out using the PKAce™ kit (Novagen) according 
to the manufacturer's protocol.  The labeling reaction was quenched with a tenfold molar excess of 
protein kinase A inhibitor (PKI 6–22 Amide, EMD Biosciences). Assays were carried out at 4 ˚C for 
20 min in 50 µl volumes containing 20 mM Tris (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 0.2 mM β-
ME, 2 mM ATP, 10 mM creatine phosphate, ten U/ml creatine kinase, 5 µM [32P]ubiquitin, 50 nM 
human E1 (Boston Biochem), 1 µM UbcH7, and 1 µM wild-type or mutant E6AP(HECT).  Reactions 
were initiated with the addition of [32P]ubiquitin and terminated with 2X SDS-PAGE loading buffer 
with or without 200 mM β-ME .  SDS-PAGE was used to separate 30 µl of the final reactions and 
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gels were then dried and exposed to a phosphor screen.  A phosphorimager and ImageQuant 5.0 
software (GE Healthcare) were used to detect and quantify [32P]ubiquitin bands.  The experiment was 
performed in duplicate (Supplementary Data, Figure 2.9). 
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SUPPLEMENTARY DATA 
 
 
Figure 2.8. Isothermal titration calorimetry of unmodified UbcH7 with E6AP. 
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Figure 2.9. Duplicate ubiquitin transfer assay with E6AP mutants.
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 CHAPTER III 
INSIGHTS INTO E2–HECT BINDING AFFINITY AND SPECIFICTY
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ABSTRACT 
It is well established that conjugation of ubiquitin to a protein substrate requires the sequential 
action of E1, E2, and E3 enzymes.  In humans a hierarchy of a single E1, roughly thirty E2s and 
hundreds of E3s allows for targeting specific protein substrates for ubiquitination.  Inherent to this 
hierarchy is the requirement for E2s to interact with multiple E3s.  Indeed this is the case for most 
E2s which can function with E3s that possess different E2-binding domains.  In contrast, a given E3 
will selectively function with E2s from one or few E2 subfamilies.  Selective E2–E3 interactions are 
important in ensuring that substrate ubiquitination is highly specific.  In humans, improper substrate 
ubiquitination can have severe consequences resulting in inherited disorders as well as acquired 
diseases and cancers.  In this study we have attempted to gain insights into E2–E3 specificity by 
identifying high affinity E2–HECT E3 interactions.  Using a quantitative binding assay we measured 
the affinity of HECT domains from Nedd4L, Smurf2, and Huwe1 proteins for fifteen E2s 
representing 11 E2 subfamilies.  Our results with Nedd4L support previous findings that have 
demonstrated HECT domains selectively interact with subfamilies of E2s.  The Nedd4L protein 
formed high affinity interactions with E2s from the UBC4/5 and E2-E subfamilies but Smurf2 did not 
display high affinity interactions with any E2s tested.  Interestingly, the Huwe1 protein did not bind 
any E2s tightly suggesting it may act in a mechanism similar to Smurf2 whereby a tertiary protein 
provides affinity and selectivity for E2s.  A better understanding of E2–E3 specificity will help in the 
development of new methods to study the pathology of ubiquitin related diseases.  
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INTRODUCTION 
Ubiquitin conjugation to a substrate requires the sequential action of E1, E2, and E3 enzymes.  In 
humans there is a hierarchy of a single ubiquitin E1, roughly 30 E2s, and hundreds of E3s.  The 
activating enzyme (E1) uses ATP to adenylate the carboxyl terminus of ubiquitin and subsequently 
forms a thioester intermediate with ubiquitin via its active-site cysteine residue.  Ubiquitin 
conjugating enzymes (E2s) bind to the E1 and form a second cysteine-mediated thioester bond with 
ubiquitin prior to binding a ubiquitin ligase (E3).  Ubiquitin ligases (E3s) are proteins or protein 
complexes that catalyze ubiquitination by selectively binding both substrate and E2.  These two 
binding events are carried out by distinct domains within a protein or by separate proteins within a 
multisubunit protein complex.  E3s enzymes can be classified by the type of E2-binding domain they 
harbor.  RING (really interesting new gene), PHD (plant homeodomain), and U-box domain E3s 
facilitate the direct transfer of ubiquitin from E2 to substrate 1; 2; 3; 4 while HECT (homology to E6AP 
carboxy terminus) domain E3s form a third thioester-intermediate with ubiquitin prior to transfer to 
substrate5.   
Much of our understanding of E2–E3 interactions at the molecular level is owed to two crystal 
structures of E2–E3 complexes.  The first structure solved was that of the E2 UbcH7 in complex with 
the HECT domain of E6AP6.  This most significant contact at the interface comes from a 
phenylalanine residue of UbcH7 that is situated at the tip of loop 4 (L4-Phe) and packs into a 
hydrophobic groove created by E6AP6.  Additional contacts from UbcH7 came mostly from helix 1 
(H1) and loop 7 (L7) with fewer contributions from loop 2 (L2)6.  The RING E3 c-Cbl was later 
crystallized in complex with the same E2 UbcH77.  This structure showed that E2s use similar 
residues to bind both RING and HECT domain E3s and that the L4-Phe again forms the most 
extensive interface contacts7.  Mounting evidence from biochemical and biophysical data suggests 
that a phenylalanine amino acid at this position is absolutely necessary for a functional E2–HECT 
interaction6; 8; 9; 10; 11.  In contrast, RING domain E3s are more tolerable to different amino acids at this 
position as functional E2–RING pairs have been identified with Asn, Tyr, His, and Leu at this 
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position.  In humans there are approximately 33 E3s of which 14 have an L4-Phe.  Nine of these E2s 
can be grouped into the UBC4/5, E2-E, and E2-L subfamilies which have all been shown to function 
with HECT E3s.  It is yet to be determined whether the five remaining E2s (UbcH2, HIP-2, 
NCUBE2, E2-T, and E2-W) will also function with HECT domain E3s.   
The hierarchal nature of the ubiquitin pathway imposes a requirement that at least some E2s must 
function with multiple E3s.  Indeed this is the case as most E2s are capable of functioning with 
multiple E3s12.  In most cases, a given E3 selectively functions with only one or few E2s.  This E2–
E3 specificity was first demonstrated with the HECT E3s Rsp5 and E6AP13.  Specific E2–E3 and E3–
substrate interactions are critical for maintaining the high specificity of ubiquitin-dependent protein 
degradation.  Dysregulation of ubiquitin substrates when E3s gain or lose function can have severe 
consequences in humans.  Inherited neurological disorders like Angelman’s syndrome and autosomal-
recessive Parkinson’s disease have been linked to the E3s E6AP14; 15 and Parkin16; 17, but the substrates 
responsible for the pathology of these diseases remain elusive12; 18; 19.  One method to identify the 
substrates of a given E3s is to isolate specific E2–E3 interactions in the cell and study the downstream 
events.  Isolating a specific E2–E3 pair in the cell could be achieved by redesigning E2–E3 interfaces 
to create altered specificity E2–E3 pairs that function with one another but no longer with their wild-
type precursors or other E2 and E3 proteins.  The E2–RING pair UbcH5b–CNOT4 has been 
successfully redesigned to interact with one another but not their wild-type precursors20.  The ability 
to rationally create altered specificity E2–E3 pairs rests on our understanding of the determinants of 
E2–E3 specificity.  In this study we have expanded upon previous work that utilized a quantitative 
binding assay to show that the HECT domain from E6AP selectively binds to the UbcH7/8 subfamily 
of E2s with high affinity11.  We have employed the same assay to measure the binding affinity of 
fifteen E2s for HECT domains from human Nedd4L, Smurf2, and Huwe1 proteins.  Our findings 
provide insight into high affinity E2–HECT pairs and the residues that dictate E2–HECT specificity.    
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RESULTS 
Recombinant ubiquitin E2 enzymes are capable of forming ubiquitin-thioester intermediates 
The E2s used in our binding assays are human proteins (except Saccharomyces cerevisiae UBC4) 
that represent 11 different E2 subfamilies (Supplementary Data, Figure 3.6).  Three of the E2s are 
conjugating enzymes dedicated to ubiquitin-like pathways.  The Ubc9 protein functions in the SUMO 
pathway, Ubc12 in the Nedd8 pathway, and UbcH8 in the ISG15 pathway.   Full length proteins for 
all fifteen E2s were purified from Escherichia coli lysates and tested for their ability to form a 
thioester intermediate with ubiquitin.   Transthiolation reactions were performed using [32P]-ubiquitin, 
E1, ATP, and an ATP regenerating system.  Separate reactions containing equal concentrations of E2s 
were allowed to proceed for 30 minutes before quenching in SDS-PAGE gel loading buffer (GLB) 
with and without β-mercaptoethanol (β-ME).  The reactions were separated by SDS-PAGE and [32P]-
ubiquitin bands were visualized using a phosphorimager.  The results for reactions quenched in GLB 
lacking β-ME show that all E2s except the those involved in ubiquitin-like protein conjugation (Ubc9, 
Ubc12, and UbcH8) were capable of forming thioester intermediates with ubiquitin (Figure 3.1(a)).  
Some E2s displayed robust transthiolation activity while others like HIP-2 and UbcH2 were much 
less active under our conditions.  Poly-ubiquitinated E2s were not observed but some E2s did display 
a second band at the expected change in MW for a second ubiquitin (~11.5 kDa).  The E1-ubiquitin 
thioester seen at the top of each lane is constant in all reactions indicating that the ATP-dependent 
activation step is not rate-limiting.  Transthiolation reactions were also quenched in buffer containing 
β-ME to break thioester bonds and detect isopeptide linkages (Figure 3.1(b)).  Interestingly, the three 
class III E2s with N-terminal extensions (UbcH10, UbcH8*, and UbcH9) all displayed β-ME resistant 
E2-ubiquitin bands suggesting these E2s possess autoubiquitination activity.  Also prominent in a few 
reactions is a β-ME resistant diubiquitin band (E2-G2 and Cdc34) that runs at ~23 kDa.  Our results 
show that our ubiquitin E2s are active and that E1-E2 transthiolation reactions proceed with differing 
kinetics and yield different ubiquitination activity.  These differences were not accounted for in 
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studies by other groups addressing E2–E3 specificity and may have led to the conflicting results that 
were often observed8; 9; 10; 13; 21; 22.      
    
The Nedd4L HECT domain selectively binds to E2s from the UBC4/5 and E2-E subfamilies 
The human Nedd4 and Nedd4L paralogs are ~80% identical in amino acid sequence across the E2-
binding region of their HECT domains suggesting that both E3s will display similar E2-binding 
preferences.  Indeed this was observed in a previous study that found both E3s preferred UbcH5a, 
UbcH5b, and UbcH7 followed by UbcH6 and UbcH9 in a substrate ubiquitination assays10.  In a prior 
study, Nedd4 autoubiquitination activity was greatest with UbcH6 and UbcH7 followed by UbcH5b 
and UbcH5c8.  Also, the UbcH9–Nedd4L interaction was identified in a two-hybrid screen and 
validated in vitro and in vivo23.  In conclusion these findings suggested that these E2s will display 
high affinity interactions with Nedd4L in our binding assay.  To monitor HECT binding to E2s we 
covalently labeled each E2 with a thiol-reactive fluorophore.  The labeling of UbcH7 with the 
identical fluorophore was previously shown to have little effect on UbcH7 binding to E6AP11.  The 
UbcH8 protein is the only E2 with a cysteine at the E3-binding interface and for this reason we tested 
the C97S mutant in our FP binding assays.  All HECT domains examined in this study 
(Supplementary Data, Figure 3.7) were purified from E.coli lysates. 
  The Nedd4L HECT domain (residues 596-975) bound to five of the E2s tested with a dissociation 
constant (KD) below 50 µM (Figure 3.2).  These five E2s are members of the UBC4/5 subfamily 
(UbcH5a, UbcH5b, and yUbc4) and the E2-E subfamily (UbcH8* and UbcH9).  The UbcH5a and 
UbcH9 proteins formed the highest affinity interactions exhibiting KD values of 4.6 µM and 8.4 µM 
respectively.  Interestingly the UbcH7 and UbcH8(C97S) proteins weakly bound to Nedd4L with 
affinities of 370 µM and 490 µM respectively (Figure 3.2).  The six E2s that lack a L4-Phe 
(Rad6b, Cdc34, E2-G2, Ubc9, UbcH10, and Ubc12) all failed to bind Nedd4L HECT with a 
measurable affinity.  The HIP-2 protein also failed to bind while UbcH2 bound Nedd4L 
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weakly (KD = 340 µM).  Our finding that Nedd4L selectively binds E2s from the UBC4/5 and 
E2-E subfamilies is consistent with previous studies10; 23.  An unexpected finding was that the 
E2-L family members UbcH7 and UbcH8 failed to bind with high affinity despite displaying 
similar conjugating activity as UbcH5a and UbcH5b10.  One explanation is that substrate 
ubiquitination assays are an indirect measure of E2–E3 binding and are less sensitive in 
detecting small differences in E2–E3 affinity because the E1–E2 reaction slow and rate-
limiting11. 
   
The E6AP HECT domain weakly binds E2s from the E2-E subfamily 
  In our previous study on E2–E6AP specificity we measured E6AP binding affinity for nine of the 
E2s used in this study11.  Of the six additional E2s used in this study, two are members of the E2-E 
subfamily (UbcH8* and UbcH9) which are class III E2s with N-terminal extensions.  These E2s are 
most similar to the UBC4/5 subfamily in residues responsible for E3 binding.  Given our finding that 
the UBC4/5 and E2-E subfamilies bound Nedd4L with similar affinity, we expected that E6AP would 
weakly interact with these E2s.  Indeed this was the case as we measured UbcH9 affinity at 140 µM 
and UbcH8* affinity at 290 µM (Figure 3.3).  We also measured E6AP affinity for the other new E2s 
(HIP-2, Cdc34, UbcH5a, and E2-G2) and found that only UbcH5a bound with detectable affinity (KD 
= 80 µM).  This value is similar to previously measured affinities for other E2s from the UBC4/5 
subfamily (Table 3.1)11.  These findings support our previous results on E2–E6AP specificity that 
showed E6AP only bound the E2-L subfamily (UbcH7 and UbcH8) with high affinity11.    
 
Smurf2 and Huwe1 HECT domains do not form high affinity E2 interactions 
A new twist on E2–E3 specificity was revealed when Ogunjimi et al showed the Smad7 protein 
was capable of recruiting UbcH7 to the Smurf2 HECT domain by directly binding to both proteins24.  
This interaction was specific for UbcH7 as the Smad7 protein was not able enhance other E2–Smurf2 
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interactions24.  The Ogunjimi et al study also showed that two Smurf2 residues (H547 and Y581) 
were disfavoring UbcH7 binding and that mutating these residues to E6AP amino acids (H547I and 
Y581F) significantly enhanced the affinity UbcH7–Smurf2 interaction24. We tested the Smurf2 HECT 
domain (residues 371-748) in our FP binding assay against our panel of E2s and found that it did not 
bind any E2s with moderate affinity except UbcH2 (KD = 320 µM).  To better estimate the affinity of 
Smurf2 for UbcH5b and UbcH7 we performed FP binding assays in which the final concentration of 
Smurf2 was increased from 250 µM to ~800 µM.  In these experiments the UbcH7 dissociation 
constant was measured at ~1.4 mM while UbcH5b binding was still undetected (data not shown).  We 
next measured the effects of the H547I and Y581F Smurf2 point mutants in our FP binding assay.  
Both Smurf2 mutants bound UbcH7 with improved affinities (KD ~ 0.5–1 mM), but given the weak 
affinity a precise measure of binding was not possible.  Our results support the Ogunjimi et al finding 
that the Smurf2 E2-binding pocket contains amino acid residues that disfavor high affinity E2-
interactions.    
The Huwe1 protein (also called ARF-BP1/Mule/HectH9) has been shown to function in vitro with 
both UbcH5a and UbcH725; 26; 27 but to our knowledge the E2 selectivity of Huwe1 has not been 
examined.  In our FP binding assay the Huwe1 HECT domain (residues 3987-4374) was unable to 
interact favorably with UbcH5a nor UbcH7 (Table 3.1).  The only E2 that formed an interaction with 
detectable affinity was UbcH2 which bound with a dissociation constant of 190 µM.  The full length 
Huwe1 protein is ~500 kDa and contains many additional domains27 that could potentially bind a 
tertiary protein and enhance an E2–Huwe1 interaction.  These findings suggest that the like Smurf2, 
Huwe1 and possibly other HECT E3s have suboptimal E2-binding grooves necessitating a tertiary 
protein for high affinity E2-interactions. 
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Engineering a tight binding UbcH7–Nedd4L pair 
An interesting question that remains is which E2 and Nedd4L amino acid side-chains are most 
responsible for forming high affinity interactions.  We previously used alanine mutagenesis and our 
FP binding assay to measure the effects of 36 single mutations at the UbcH7–E6AP interface11.  In 
that study we found four UbcH7 side-chains (P62, F63, K96, and K100) contributed more than 1 
kcal/mol to the free energy of binding and that two mutations to UbcH5b (L3S and T98K) were able 
to enhance UbcH5b–E6AP affinity from 160 µM down to 7.4 µM11.  We aligned the primary 
sequences of the 15 E2s used in this study (Supplementary Data, Figure 3.6) and analyzed the 
subset of residues that interact E3s (Figure 3.4). We first mutated the L7-UbcH7 lysines to the 
corresponding amino acids found in the UBC4/5 and E2-E subfamilies (K96S and K100T).  We 
measured binding of these UbcH7 mutant proteins against both E6AP and Nedd4L.  The K96S 
mutation had little impact on E6AP binding yet was able to promote a tighter UbcH7–Nedd4L 
interaction (∆∆G°bind = –0.5 kcal/mol) (Table 3.2).  In contrast the K100T mutation showed reduced 
binding to E6AP (∆∆G°bind = 0.8 kcal/mol) while binding Nedd4L with wild-type affinity.  We also 
tested the A59T UbcH7 mutation because threonine is seen at this position in the UBC4/5 subfamily.  
We found that E6AP disfavored this mutation (∆∆G°bind = 0.7 kcal/mol) while Nedd4L preferred a 
threonine (∆∆G°bind = –0.4 kcal/mol).  We next tested if the A59T–K96S double mutant would 
display an additive enhancement to binding Nedd4L.  To our surprise the effects on binding were 
non-additive as the double mutant bound Nedd4L no tighter than either single mutation.  This 
observation was not observed for E6AP which bound A59T–K96S with additive effects of each 
single mutant (∆∆G°bind = 0.8 kcal/mol).  The S4L mutation is yet to be tested and may be necessary 
for obtaining a high affinity UbcH7–Nedd4L pair.     
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DISCUSSION 
In this study we measured the dissociation constant for fifty E2–HECT interactions in an effort to 
better understand amino acid residues that dictate E2–HECT specificity.  The importance of a L4-Phe 
residue for HECT binding is demonstrated again as none of the E2s lacking this phenylalanine bound 
to any HECT with detectable affinity.  We have found that like E6AP, the HECT domain of Nedd4L 
selectively forms high affinity E2 interactions.  Unlike E6AP which prefers the E2-L subfamily, 
Nedd4L preferentially bound E2s from UBC4/5 and E2-E subfamilies.  The E2–Nedd4L interactions 
displaying tightest binding were UbcH9 and UbcH5a with dissociation constants below 10 µM and 
quite similar to values of those measured for E6AP binding to UbcH7 and UbcH811.  The binding of 
Nedd4L to UbcH7 and UbcH8 (370–490 µM) was weaker than E6AP binding to UBC4/5 and E2-E 
subfamily members (80–290 µM).  The Smurf2 and Huwe1 HECT domains exhibited similar 
behavior in that neither bound any E2s with high affinity.  The only E2 that bound with detectable 
affinity was the UbcH2 protein which formed weak interactions with both HECT domains.  The 
Smurf2 protein has been shown to have a non-optimal E2-binding site and to function in conjunction 
with Smad7 to selectively bind UbcH724.  Though the effects of Smad7 on the UbcH7–Smurf2 
interaction has not been addressed in this work, a ~1000-fold increase in binding affinity would be 
necessary to approach the affinity of tight binding E2–HECT pairs.  Our findings with the Huwe1 
HECT domain suggest that it also requires an additional protein factor for tight E2-binding.  It is 
possible that an untested human E2 with a L4-Phe could form favorable interactions with Smurf2 or 
Huwe1, but we do not believe this will be the case as Nedd4L and E6AP both maintain weak affinity 
for non-preferred E2s. 
In a previous work on UbcH7–E6AP specificity, we measured the change in UbcH7 affinity for 
E6AP upon mutating 18 individual side-chains to alanine11.  To map these positions on other HECT 
domains we performed a structure-guided alignment of the HECT domains examined in this study.  
Crystal structures of the HECT domains of Smurf224, Nedd4L28, and E6AP6 were used to perform a 
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structural alignment of their ~80 amino acid E2-binding domains.  The structurally defined portions 
of the E2-binding domains aligned well allowing us translate E6AP residues to the other HECT 
domains with confidence.  The alignment (Figure 3.5(a)) shows that the loop connecting H7 and S5 
is 1–3 residues longer in E6AP and the S5-S6 hairpin in E6AP has a leucine insertion.  The 18 
interface positions mutated to alanine in our previous work were mapped onto the aligned HECT 
structures (Figure 3.5(b)).  We first looked for differences in Huwe1 relative to E6AP in effort to 
identify residues that potentially disfavor binding to all E2s.  Some of the differences are common to 
Nedd4L suggesting that they are not responsible for disfavoring all E2 interactions.  For example the 
F690 E6AP side-chain is present as a tyrosine in the other E3s; we have measured the effects of the 
F690Y E6AP mutation on binding UbcH7 and found that though destabilizing, the interaction was 
not abolished (KD = 53 ± 12 µM, unpublished results).  The Huwe1 HECT has unique substitutions 
that are seemingly destabilizing at E6AP residues V634(H), S638(G), D652(G), and M653(Y).  The 
H547 position in Smurf2 is a leucine in Huwe1 suggesting that the two HECT disfavor binding E2s 
using different side-chains. 
In this study we also found that two mutations to UbcH7 that were able to provide marginal 
improvements to Nedd4L binding affinity.  It is likely that the threonine side-chain in the A59T-
UbcH7 protein is forming a hydrogen bond with the D778 Nedd4L side-chain.  This hydrogen bond 
would be absent in the wild-type UbcH7–E6AP interaction because E6AP has a serine amino acid at 
this position.  In support of this potential hydrogen bond interaction is our finding that the A59T-
UbcH7 mutant bound E6AP with reduced affinity.  The K96S-UbcH7 protein is likely enhancing 
affinity by relieving a steric clash imposed by the wild-type lysine with the Nedd4L W762 side-chain.  
Our findings with E6AP suggest that a serine residue at this position in UbcH7 may be capable of 
retaining a hydrogen bond with the D641 E6AP side-chain.  The K100T mutant bound both E6AP 
and Nedd4L with reduced affinity suggesting that this threonine is too distant from the HECT 
domains to form interactions.  We observed that the double mutant A59T–K96S did not bind Nedd4L 
with additive effects of both mutations.  This was similarly observed when reengineering the 
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UbcH5b–E6AP interaction as the S94K UbcH5b mutation reduced binding alone or in the presence of 
T98K, but had no effect in the presence of the L3S mutation11.  This suggests that optimizing a cluster 
of interacting residues at a given E2–HECT interface may alter interface interactions at distal 
positions.  Other mutations to UbcH7 that have not been tested but may prove important for UbcH7–
Nedd4L affinity are S4L and R5K.  The R5K mutant may allow for a hydrogen bond with Nedd4L 
D772, which is a methionine residue in E6AP (M654).  The results from this work will aid efforts 
attempting to redesign E2–E3 interactions to better understand the pathology of ubiquitin-related 
diseases.    
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FIGURES 
 
Figure 3.1. E1–E2 transthiolation assay.  The 15 recombinant E2s were tested for their ability form 
ubiquitin thioester intermediates.  Equal concentrations of each E2 were incubated with E1, [32P]-
ubiquitin, ATP, and an ATP regenerating system and allowed to proceed for 30 minutes at 25° C.  
Reactions were quenched in SDS-PAGE gel loading buffer without (A) and with 100 mM β-ME (B).  
All ubiquitin E2s were capable of forming thioester intermediates while E2s belonging to the Nedd8 
(Ubc12), SUMO (Ubc9), and ISG15 (UbcH8) pathways were not.    
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Figure 3.2. The Nedd4L HECT domain selectively interacts with E2s from the UBC4/5 and E2-E 
subfamilies.  The Nedd4L HECT domain was tested in FP binding assays against the 15 E2s.  
UbcH5a and UbcH9, members of the UBC4/5 and E2-E subfamilies, bound Nedd4L with 
dissociation constant below 10 µM.  Other members of these subfamilies formed favorable 
interactions with Nedd4L (UbcH5b, yUbc4, and UbcH8*).   
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Figure 3.3. E6AP weakly interacts with the UBC4/5 and E2-E subfamily of E2s.  The E6AP HECT 
domain was tested in the FP assay and found to weakly interact with UBC4/5 and E2-E subfamily 
members.  This is in agreement with previous results that showed E6AP selectively binds the E2-L 
subfamily E2s UbcH7 and UbcH811. 
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Figure 3.4. Multiple sequence alignment of the E3-binding residues of the 15 E2s used in this study.   
Red dots indicate positions that were previously found to be important for UbcH7–E6AP binding 
affinity and specificity11.  The E2s that interact most favorably with Nedd4L have an S/T at the first 
position in loop 4, a S at the fifth position in loop 7, and a T at the last position in loop 7.. 
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Figure 3.5. E2–Nedd4L specificity determining residues.  (A) Multiple sequence alignment of the 
E2-binding domains of the 4 HECT E3s examined in this study.  Red dots indicate residues that were 
previously shown to be important for UbcH7–E6AP binding affinity11.  (B) Superimposition of the 
E2-binding residues of the E6AP, Nedd4L, and Smurf2 HECT domains.  Highlighted side-chains are 
interface residues that were previous analyzed by alanine mutagenesis and the FP assay11. 
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MATERIALS AND METHODS 
Protein Purification 
Expression plasmids and purification schemes for Rad6b, UbcH2, yUbc4, UbcH5b, UbcH7, 
UbcH8, UbcH10, Ubc9, Ubc12, E6AP(HECT), and ubiquitin have been described11; 29.  Expression 
plasmids for UbcH8*, E2-G2, HIP-2, and Cdc34 were subcloned from MGC clones (Open 
Biosystems) into the pGEX-4T-1 expression vector (GE Healthcare).  Many groups kindly 
contributed plasmids used in this study.  UbcH9 (from pGEX*, Marc Timmers), UbcH5a (from pET-
3a, Jon Huibregtse), and Nedd4L (from pRK5, Fiona McDonald) were subcloned in pGEX-4T-1.  
Plasmids encoding Huwe1 HECT domain (pGEX-2TK, Jean Cook) and Smurf2 HECT domain 
(pGEX-4T-1, Tony Pawson) were in suitable vectors for bacterial expression.  Single point mutations 
were generated using the QuickChange® site-directed mutagenesis protocol (Stratagene).  All 
proteins were expressed in the BL21(DE3) strain of E.coli at 25° C for ~16 hours using 0.3 mM 
IPTG.  Resuspended cells were disrupted by sonication and the resulting lysates was cleared by 
ultracentrifugation.  All proteins were purified using glutathione Sepharose followed by thrombin 
cleavage to remove the GST-tag, anion exchange chromatography, and finally size-exclusion 
chromatography.  Proteins were concentrated using Centriprep® and Centricon® concentrators and 
were quantified using extinction coefficients derived from the method describe by Gill and von 
Hipple30. 
 
E1–E2 transthiolation assay 
Ubiquitin was expressed and purified with an N-terminal protein kinase A (PKA) recognition site.  
Isotopic labeling of ubiquitin with [32P] was carried out using the PKAce™ kit (Novagen) according 
to the manufacturer’s suggested protocol.  A coomassie-stained SDS-PAGE gel was run to ensure 
equal concentrations of E2 were present in each reaction (data not shown).  Reactions of 50 µl 
volumes containing 20 mM Tris (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 0.2 mM β-ME, 2 mM ATP, 
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10 mM creatine phosphate, 10 U/ml creatine kinase, 10 U/ml inorganic pyrophosphatase, 1 mM 
PMSF, 100 nM E1 (Boston Biochem), 13 µM [32P]-ubiquitin, and 5 µM E2 were allowed to proceed 
for 30 min at 25°C.  Reactions were initiated with [32P]-ubiquitin and quenched in SDS-PAGE gel-
loading buffer with and without 100 mM β-ME.  Twenty microliters of each transthiolation reaction 
was separated by SDS-PAGE and the resulting gels were dried and exposed to a phosphor screen.  
Ubiquitin and ubiquitinated proteins were visualized using a phosphorimager (GE Healthcare). 
 
Fluorescence polarization binding assay 
A detailed method describing the E2 fluorophore-labeling reaction with bodipy (507/545)-
iodoacetamide has been described29.  Binding assays were performed at room temperature in 20 mM 
KH2PO4 (pH 7.0), 150 mM NaCl, and 5 mM β-ME.  For almost all binding measurements the HECT 
E3 was stock solution was approximately 300 µM.  The starting concentration of each E2 varied from 
0.5 µM to 2 µM and was dependent on the extent of labeling with bodipy.  In each experiment, the 
polarization of bodipy-E2 was recorded at twenty concentrations of HECT domain.  At each HECT 
concentration nine polarization readings were collected and averaged.  Binding data were fit to a 
single-site binding model using non-linear regression in SigmaPlot as previously described29.  Data 
analysis in SigmaPlot yields parameters for Pmin (starting polarization) Pmax (maximum polarization) 
and KD (dissociation constant).  Weak E2–HECT interactions tended to fit to the maximum allowable 
Pmax (0.5) with micromolar KDs and high standard errors. The Pmin for each E2 varied, but the change 
in polarization (Pmax–Pmin) observed for high affinity E2–HECT interactions typically fell in the range 
of 0.09 to 0.11. The UbcH2 protein, which bound all HECT domains tested with marginal affinity, is 
the only exception and it displayed a change in polarization of ~0.3 when bound to a HECT domain.   
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SUPPLEMENTARY DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Sequence alignment of the 15 E2s used in this study. 
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Figure 3.7. Sequence alignment of the four HECT E3s used in this study. 
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MODULATING E2–HECT BINDING AND SPECIFICITY
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ABSTRACT 
A variety of human disease and disorders stem from E3 improperly regulating the ubiquitination of 
substrate proteins.  In some cases, like Angelman’s syndrome and Liddle’s syndrome, E3s or 
substrates acquire mutations that reduce or abolish ubiquitination resulting in stabilization of the 
substrate in the cell.  In other cases like the human papillomavirus, E3s gain function and ubiquitinate 
improper substrates resulting in their degradation.  Though direct links to E3s have been made, the 
substrates and pathology of some disease remain unclear.  Detecting the substrates of a given E3 has 
proven to be a challenging task.  The hierarchal nature of the ubiquitin pathway presents a formidable 
obstacle in detecting all E2–E3 and E3–substrate interactions.  One approach to dissecting these 
interactions is to design altered specificity E2–E3 pairs that function with one another, but not other 
natural partners.  In this fashion a particular E2–E3 interaction could be isolated in the cell so that the 
downstream consequences of this interaction can be studied.  The creation of altered specificity E2–
E3 pairs can be achieved by designing orthogonal E2–E3 interfaces.  A given E2-E3 pair is 
redesigned so that they function well with each other but not their wild-type (WT) precursors.  
Orthogonal E2–E3 pairs have potential to be bona fide altered specificity pairs because interactions 
that disrupt binding to the WT precursors will likely disrupt binding to other natural partners.  In this 
study we have used a combination of computational protein design and rational engineering to 
manipulate E2–E3 interactions.  Combining results from both methods we created a UbcH7–E6AP 
pair that binds ~1000 times stronger than the WT interaction. 
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INTRODUCTION 
It has become evident that ubiquitin-mediated protein degradation influences nearly all cellular 
processes and pathways1.  It is also well established that various human diseases and disorders are 
consequences of E3s improperly regulating their substrates2; 3.  For example, inherited disorders such 
as Angelman’s syndrome, Liddle’s syndrome, and autosomal recessive Parkinson’s disease (AR-PD) 
have been linked to E3s that can no longer fulfill their cellular roles4; 5; 6; 7; 8.  In Liddle’s syndrome, 
the HECT E3 Nedd4 no longer binds to or ubiquitinates the epithelial Na+ channel (ENaC) ultimately 
resulting in stabilization of ENaC, increased Na+ uptake and hypertension9; 10.  In approximately 75% 
of patients with Angelman’s syndrome, the maternal copy of the gene encoding the HECT E3 E6AP 
has been entirely deleted or has acquired mutations11 that have been shown to reduce ligase activity11; 
12; 13.  Though a handful of E6AP substrates have been identified13; 14; 15; 16; 17; 18, none have been 
implicated in the etiology of Angelman’s syndrome.  Similarly, approximately 50% of patients with 
AR-PD have acquired mutations to the gene encoding a RING E3 Parkin19 but the link between 
Parkin substrates and the etiology of AR-PD remains unclear20; 21.  The identification of all the 
substrates of a given E3 would aid in the study of diseases stemming from the ubiquitin pathway.   
The identification of all the substrates of a given E3 is a challenging but very important task.  
Previous methods have relied on a variety of techniques including two-hybrid screens and 
coimmunoprecipitations.  Though both approaches have led to the identification of numerous E3 
substrates, both are inherently limited when applied to detecting interactions within the ubiquitin 
pathway.  The two-hybrid screen is usually performed in a host system so E3 substrates that require 
phosphorylation or other post-translational modifications prior to recognition by E3 may not bind E3 
with sufficient affinity for detection.  Coimmunoprecipitations are limited by the stability of the 
ubiquitinated substrate as deubiquitinating enzymes and the 26S proteasome function to remove 
ubiquitin and degraded the substrate.  Inhibitors of the proteasome and deubiquitinating enzymes can 
be useful but again the context of the interaction has been altered.  The hierarchy of the ubiquitin 
pathway complicates matters because each E2 functions with many E3s3.  While E3s can interact with 
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multiple E2s, these E2s are usually highly homologous and stem from similar E2 subfamilies.   
Clearly a better approach to identifying E3 substrates is needed.  An ideal method would allow for the 
detection of low-affinity E3–substrate interactions without significantly perturbing the cellular 
environment.  One way to create such a tool is by creating altered specificity E2–E3 pairs. 
The manipulation of an E2–E3 pair has been demonstrated previously22.  A charge swap 
interaction was generated across the UbcH5b-CNOT4 interface to create a mutant pair that no longer 
interacted with the WT precursors22.  In this study the authors claim to have generated an altered 
specificity pair but the mutant proteins were not tested against other natural partners.  A bona fide 
altered specificity E2–E3 pair must display two characteristics.  First, the redesigned E2 and E3 
proteins must interact favorably with one another but not with their wild-type precursors.  Redesigned 
E2–E3 pairs displaying this property will be referred to as orthogonal E2–E3 pairs.   Second, the 
redesigned E2–E3 pair should no longer interact favorably with other naturally occurring partners.  
This is property is most important for E2s because each E2 usually interacts with multiple E3s3.  
Orthogonal E2–E3 pairs have potential to be bona fide altered specificity pairs because interactions 
that disrupt binding to the WT precursors will likely disrupt binding to other natural partners.  In this 
study we have used a computational protein design and rational engineering to generate orthogonal 
E2–E3 interfaces and to enhance E2–E3 affinity.  We have used the UbcH7–E6AP interaction as a 
model system for these studies. 
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RESULTS 
Manipulation of K96–D641 interaction 
We previously found that the K96 residue of UbcH7 is important for E6AP binding and 
specificity23.  In the WT UbcH7–E6AP interaction this lysine, situated on loop 7, forms a salt-bridge 
interaction with D641 of E6AP.  We previously used the interface design algorithm of RosettaDesign 
to create an enhanced affinity K96S-UbcH7–D641K-E6AP (K96S–D641K) pair24.  The K96S–
D641K pair bound with a KD of 100 nM, a significant enhancement relative to the WT interaction 
(∆∆G°bind of –2.3 kcal/mol).  We also tested the K96E–D641K pair for a charge swap interaction and 
again observed an improvement to binding (∆∆G°bind of –0.8 kcal/mol)23.  The mutant proteins were 
also tested with their WT partners to test for orthogonal interfaces.  The D641K and K96S proteins 
bind their WT partners with roughly the same affinity as the WT interaction whereas the K96E 
mutant was destabilizing (∆∆G°bind of +1.2 kcal/mol)23. The interface design protocol was again 
applied to the K96–D641 interaction to test for other mutations that may yield an orthogonal 
interface.  RosettaDesign predicted that mutations to Trp or Tyr at both positions would generate an 
enhanced affinity interaction.  An orthogonal interface was not predicted because the D641Y/W 
mutants were predicted to enhance affinity WT-UbcH7.  We made the K96Y, K96W, D641Y, and 
D641W mutant proteins and tested them in our binding assay.  Indeed all four mutant interactions 
were capable of enhancing affinity with similar gains in binding affinity (KD = 470–610 nM) (Figure 
4.1).  We next tested the effects of the D641Y/W mutations on binding to WT-UbcH7 and found that 
these mutations indeed enhanced affinity (KD = 0.8–1.2 µM)25.  The K96Y/W mutants bound WT-
E6AP slightly weaker than WT-UbcH7 (KD = 7.2–8.7 µM).  The results from manipulating the K96–
D641K interaction suggest that these positions may be amenable to manipulation in other E2–HECT 
pairs. 
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Redesigning other loop 7-UbcH7–E6AP interactions 
Other loop 7-UbcH7 side-chains that interact with E6AP include E93, W95, P97, A98, and K100.  
The W95 residue is completely conserved in all E2s and P97 is highly conserved suggesting these 
residues are important for structural orientation of loop 7.  We avoided redesigning the residues, but 
mutations at E93, A98, and K100 were tested.  The K100E–D652R mutants were previously tested 
for a charge swap interaction and the mutant complex was slightly more destabilizing than either 
single mutation23.  RosettaDesign predicted a cluster of mutations around A98 would form an 
orthogonal interface.  The three mutations (A98W–Y645W-D652W) were all to Trp and an increase 
in buried hydrophobic surface area upon binding was the physical basis for the predicted gain in 
binding energy.  We first tested the A98W–Y645W pair for an orthogonal interface and found that the 
mutant interaction indeed bound tighter than the WT interaction (KD = 480 nM) (Figure 4.1).  This 
gain in binding energy was entirely attributed to A98W as this mutant bound WT-E6AP with a KD of 
190 nM25 while the Y645W-E6AP protein bound WT-UbcH7 with WT affinity.  The D652W 
mutation was tested in combination with Y645W and it proved to provide a more orthogonal interface 
as it destabilized binding to both WT and A98W-UbcH7 by ~1.5 kcal/mol.   
In the UbcH7–E6AP crystal structure, coordinates for the E93 side-chain are absent.  This is likely 
the result of a high temperature factor and inconclusive electron density.  We used RosettaDesign to 
model this side-chain and found no contacts to E6AP.  This was a surprising result given the E93A 
and E93R mutations were both found to stabilize binding to E6AP (KD = 2.4 and 0.92 µM 
respectively)23.  To test whether E93 may be engaged in an interaction with Q637 of E6AP, the 
Q637A and Q637R mutant proteins were tested with WT-UbcH7.  We found these mutations 
displayed similar affinities as E93A and E93R (Figure 4.1).  This finding suggested that the E93A 
and Q637A mutations were either relieving an unfavorable interaction (steric or electrostatic clashes) 
or that they were allowing alternate structural arrangements.  The E93R and Q637R mutations may 
allow for a new salt-bridge/hydrogen bond interaction across the interface.  We tested this 
interpretation by measuring the affinity of the E93A–Q637R and E93R–Q637A interactions.  In both 
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cases, the measured change in binding energy was roughly the sum of the change of the individual 
mutations (Figure 4.1).  The additive effects argues against these side-chains forming interactions 
when either is mutated to an arginine.  The changes in interface interactions imposed by the E93A/R 
and Q637A/R mutations remain unknown.  The Q637W mutation was identified in search of 
mutations that enhance affinity by increasing buried hydrophobic surface area.  This mutant was 
found to bind WT-UbcH7 with a slightly improved affinity (KD = 1.7 µM)25. 
 
Manipulating loop 4 of UbcH7 
The most important contact at the UbcH7–E6AP interface arises from a F63 which is situated at 
the tip of loop 4.  All E2s that interact with HECT E3s contain a phenylalanine at this position23; 26; 27.  
Roughly half of the human E2s have a phenylalanine at this position whereas the rest possess a 
mixture of polar, charged, aromatic, and hydrophobic amino acids.  We tested the effects of mutating 
F63-UbcH7 on binding E6AP.  The F63A and F63D mutations were previously shown to abolish 
binding to E6AP23; 24.  More conservative substitutions at this position (F63Y, F63H, and F63W) led 
to less pronounced destabilizations (Table 4.1).  The F63W mutant, which was predicted by 
RosettaDesign to slightly improve E6AP binding has the least effect (∆∆G°bind of +0.7 kcal/mol)25.  
The F63H and F63Y mutants bound much weaker with destabilizations of 2.0 and 1.3 kcal/mol 
respectively.  The F63H–F690Y design was predicted as orthogonal by RosettaDesign, but these 
mutants failed to form a favorable interaction.  These results, along with others, emphasize the 
importance of the tightly packed hydrophobic interface core. 
Flanking the F63 residue are the E60 and K64 side-chains.  These residues form a salt-bridge 
interaction with each other and E60 also forms a hydrogen bond with T662-E6AP.  The E60A and 
E60R mutations have been shown to have a small effect on E6AP affinity, while K64A and K64R 
displayed more pronounced destabilizations23.  We used RosettaDesign to redesign interactions at 
these two positions.  For the E60 position, RosettaDesign predicted a cluster of mutations to 
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hydrophobic residues in place of the E60–T662 hydrogen bond (E60L–T662F-Q661F).  We tested for 
orthogonal interactions and found that the E60L–T662F and E60L–T662F-Q661F proteins bound 
slightly weaker than the WT interaction (Figure 4.1).  Furthermore, the T662F and T662F-Q661F 
proteins bound WT-UbcH7 with WT affinity while the E60L effect was more destabilizing (∆∆G°bind 
of +0.6 kcal/mol).  The K64L mutation was successfully predicted by RosettaDesign to enhance 
affinity for E6AP25.  The aliphatic portion of the K64 side-chain is in the vicinity of V634 and 
RosettaDesign predicted an orthogonal K64E–V634R interaction.  When tested the V634R-E6AP 
mutant with WT-UbcH7 and found a loss in binding energy of 0.5 kcal/mol (Figure 4.1).  
Unfortunately the K64E–V634R interaction was more unfavorable than either single mutation 
(∆∆G°bind of +1.0 kcal/mol).  A similarity in these findings is that RosettaDesign is capable of 
destabilizing interactions but has difficulty in recovering the lost binding energy. 
 
Combining mutations to generate orthogonal UbcH7–E6AP pairs 
Using the results from these redesign efforts we sought to combine mutations to generate high 
affinity and orthogonal UbcH7–E6AP pairs.  We first tested whether affinity enhancements observed 
with loop 7 mutations could be combined for additive stabilizations.  The K96S–D641K pair was 
tested with additional E93R and A98W mutations.  We found that indeed both mutations were able to 
significantly enhance binding affinity.  The E93R-K96S–D641K pair interacted so strongly that it 
was difficult to measure the affinity with precision in our FP assay.  A good estimate of this affinity 
(KD of ~2 nM) indicates greater than additive effects to the binding affinity (Figure 4.1).  The K96S-
A98W–D641K pair bound with a KD of 12 nM and slightly less than additive effects.  We next tested 
the E93R-K96S-A98W-UbcH7 protein with D641K and found that the additional mutation slightly 
weakened binding displaying a KD of 27 nM.  Interestingly the K96S-A98W-UbcH7 protein bound 
WT-E6AP with a KD of 4.2 µM, an affinity much weaker than expected based on the results from 
each single mutation. 
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Given the significant gains in binding affinity observed with E93R-K96S–D641K and K96S-
A98W–D641K pairs, we next tested whether adding F63A/H/Y would help in achieving an 
orthogonal interaction.  Our findings (Table 4.1) show that the loop 7 mutations indeed can 
compensate for lost binding energy from the F63A/H/Y mutations.  The F63Y mutation which was 
the least destabilizing of the three bound with KD of 600–850 nM when combined with loop 7 
mutations.  The F63H mutation with loop 7 mutations bound with WT affinity (KD of 2.5–4.3 µM) 
while F63A binding was much weaker (92–120 µM).  These UbcH7 mutants were tested with WT-
E6AP and found to bind much weaker relative to D641K-E6AP (∆∆G°bind of 1–2.5 kcal/mol).  
Because the D641K mutation is not destabilizing relative to WT binding23, these mutant pairs should 
not be considered orthogonal.  Given E6AP only binds tightly to UbcH7 and UbcH8 while UbcH7 
functions with many E3s, we are more concerned with disrupting natural UbcH7–E3 interactions.  
Specificity in this direction is also more important in our system because we are more concerned with 
our redesigned E2s not being able to pass Nedd8 onto naturally occurring E3s.  Redesigned E3s 
interacting with natural E2s is tolerable because the outcome is that these E3s will ubiquitinate their 
natural substrates.  
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DISCUSSION 
In this study we have used a combination of computational interface design and rational 
engineering to modulate the binding affinity of the UbcH7–E6AP interaction.  Our findings suggest 
that UbcH7 loop 7 is most amenable to reengineering because it lies on the periphery of the interface 
and forms many contacts to E6AP.  Using RosettaDesign to engineer orthogonal and enhanced 
affinity interactions we were able to find several mutations that stabilized binding.  Though not 
completely successful at generating orthogonal interfaces, RosettaDesign in most cases showed 
success in either stabilizing or destabilizing interactions.  By combining results from both 
computational and rational engineering we were able to create a UbcH7–E6AP pair that bound 
roughly 1000 times stronger than the WT interaction (5.0 µM versus ~2 nM).  Using this approach we 
were also able to generate a pseudo-orthogonal interaction around F63Y and F63H of UbcH7.  
Because few E2s possess Tyr and His at this position, this mutant UbcH7 may prove quite effective at 
disfavoring interactions with other natural E2s.  An interesting question that remains is whether the 
effects seen for A98W, E93R, and K96S–D641K will translate to other E2–HECT interactions. 
81 
FIGURES 
 
Figure 4.1. Binding results from orthogonal and rational designs of the UbcH7–E6AP complex.  
Values are measured dissociations (µM) and the associated standard error.
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TABLES 
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MATERIALS AND METHODS 
Protein purification and FP binding assays 
The protocol for expression and purification of UbcH7 and E6AP has been described24.  UbcH7 
and E6AP mutations were generated using the QuickChange® site-directed mutagenesis protocol 
(Stratagene).  A detailed method describing the labeling of E2s with bodipy (507/545)-iodoacetamide 
(Molecular Probes) has been described23; 24.  The FP binding assay has also been described in detail in 
previous reports23; 24. 
     
RosettaDesign 
Predictions for the K64L, F63W, and Q637W affinity enhancing mutations were carried out by 
Deanne Sammond and has been previously described25.  The interface mode of RosettaDesign was 
used to predict orthogonal interactions.  The protocol is based on a ‘computational second-site 
suppressor’ method developed by Kortemme et al.28.  Briefly, the atomic coordinates of the UbcH7–
E6AP crystal structure26 were read by RosettaDesign.  All interface positions are identified by the 
algorithm..  Negative design ensues as the algorithm tests all amino acids at each interface position to 
find destabilizing mutations.  Positive design follows for each destabilizing point mutation in attempt 
to restore or increasing binding affinity.  The final step is the calculation of energies for the free 
proteins (WT and mutants) as well as the complexes (WT–WT, WT–MUT, MUT–WT, and MUT–
MUT).  From these energies the changes to the free energy of binding are calculated then ranked.  
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ABSTRACT 
During ubiquitin ligation, an E2 conjugating enzyme receives ubiquitin from an E1 enzyme and 
then interacts with an E3 ligase to modify substrates. Competitive binding experiments with three 
human E2-E3 protein pairs show that the binding of E1s and of E3s to E2s are mutually exclusive. 
These results imply that polyubiquitination requires recycling of E2 for addition of successive 
ubiquitins to substrate.
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MAIN TEXT 
Post-translational modification by ubiquitin and ubiquitin-like proteins (ubls) regulates almost all 
aspects of cellular function. Although it is known that E1, E2 and E3 enzymes work together in a 
cascade to transfer ubiquitin and ubls, the mechanism and assembly of the cascade are incompletely 
understood. It is not known whether the process involves sequential E1-E2 and E2-E3 interactions, 
with E2 disengaging from E1 before it can interact with an E3, or whether the E1, E2 and E3 enzymes 
function as a single complex. The answer to this question has important implications for the nature 
and processivity of ubiquitin and ubl transfer. 
Indirect evidence from structural studies indicates that the E3-binding site on ubiquitin E2s may 
partially overlap with the E1-binding site. Residues on the N-terminal helix of the E2 UbcH7 interact 
with the HECT domain E3 E6AP1 and the RING domain E3 c-Cbl2 and correspond with residues on 
Ubc12, the conjugating enzyme for the ubl NEDD8, that interact with its E1, APPBP1-UBA3 (ref. 3). 
To determine whether a HECT E3 is capable of inhibiting the E1-E2 interaction, we examined the 
effects of increasing concentrations of the E6AP-HECT domain on the initial rate of E1-UbcH7 
transthiolation. To simplify the reaction, we used a catalytically inactive variant of E6AP (C820A) 
that cannot receive ubiquitin from E2, but binds to E2 with wild-type affinity (Fig. 5.1 and 
Supplementary Data, Table 5.1). Kinetic ubiquitination assays in vitro revealed that the initial rate 
of formation of the UbcH7−[32P]ubiquitin thioester depends on the concentration of C820A-HECT. A 
modified Michaelis-Menten scheme was derived and used to fit the kinetic data to determine an 
inhibition constant (Ki) of 3.1 µM for the UbcH7–C820A-E6AP interaction (Fig. 5.1b, 
Supplementary Data, Methods and Fig. 5.3).  To verify that the Ki corresponds to binding between 
E3 and E2, we monitored binding directly by fluorescence polarization of BODIPY-labeled UbcH7 as 
a function of E6AP concentration. The measured Kd, 6.0 µM, is very similar to the Ki.  In a second set 
of experiments, we assessed the changes in the kinetic parameters kcat and Km for E1-E2 
transthiolation in the presence of high concentrations of C820A-HECT and found that inhibition is 
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due to competitive binding, as the Km for the E1-E2 interaction was compromised (1.7 µM versus 18 
µM), whereas kcat was largely unchanged (0.4 s-1 versus 0.5 s-1; Supplementary Data, Fig. 5.4). 
To further confirm that the HECT domain is capable of inhibiting UbcH7 transthiolation, we used 
RosettaDesign4 to engineer an enhanced affinity UbcH7-E6AP pair (K96S-UbcH7 and D641K-E6AP, 
Kd = 0.10 µM; Supplementary Data, Methods).  With the designed E2-E3 pair, the E3 inhibits 
UbcH7 transthiolation at lower concentrations of E3 (Ki = 0.33 µM).  Additionally, a UbcH7 variant 
(F63D) that binds very weakly to E6AP (Kd > 100 µM) did not inhibit the conjugation of ubiquitin to 
UbcH7.  Because E2s do not change conformations substantially upon binding E3s or E1s (refs. 1–
3,5,6), our results suggest that UbcH7 contains overlapping binding sites for E1 and E3 that prevent 
the formation of a ternary E1–UbcH7–HECT complex. 
To determine whether E1-binding sites on E2s are also involved in downstream interactions in 
RING E3-dependent ubiquitin and ubl transfer, we studied the effects of adding E2-binding domains 
from E1s to chase assays examining ubiquitin and NEDD8 transfer from their respective E2s to 
targets.  For a RING E3 in the ubiquitin pathway, we examined SCFβ-TRCP-mediated transfer of 
ubiquitin from the ubiquitin E2, UbcH5b, to a target peptide from β-catenin.  For the NEDD8 
pathway, we looked at Rbx1- or Roc1- mediated transfer of NEDD8 from the NEDD8 E2, Ubc12, to 
Cul1.  Because the isolated fragments corresponding to the E2-binding domains from ubiquitin's and 
NEDD8's E1s bind UbcH5b and Ubc12, respectively (ref. 3 and D.M.D., unpublished results), these 
domains from E1s inhibit transfer of ubiquitin or NEDD8 from their E1s to their specific E2s (ref. 3; 
Fig. 5.2). Therefore, chase assays, which are not sensitive to inhibition of E1-mediated transfer of 
ubiquitin or NEDD8 to E2, must be used to monitor transfer of ubiquitin or NEDD8 to their targets. 
These assays require two steps. First, the UbcH5b-[32P]ubiquitin or Ubc12-[32P]NEDD8 thioester 
intermediate is generated by mixing the appropriate E1 and E2, MgATP, and [32P]ubiquitin or 
[32P]NEDD8, respectively. This first reaction is quenched, so that the chase reaction is not sensitive to 
any effects on E1-E2 interactions. In the second step, after formation of the UbcH5b-[32P]ubiquitin or 
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Ubc12-[32P]NEDD8 thioester complex is quenched, we add the E3 and target and monitor the transfer 
of [32P]ubiquitin or [32P]NEDD8 from E2 to the target. Addition of the ubiquitin E1's E2-binding 
domain inhibited SCFβ-TRCP-mediated transfer of ubiquitin from UbcH5b to the β-catenin peptide 
target (Fig. 5.2b).  The control containing the Ubc12-binding domain from NEDD8's E1 indicated 
that this inhibition is specific for ubiquitin E1-E2 interactions (Fig. 5.2b). Parallel results were 
obtained with the NEDD8 pathway. Addition of the NEDD8 E1's E2-binding domain inhibited Rbx1- 
or Roc1-mediated transfer of NEDD8 from Ubc12 to Cul1 (Fig. 5.2d), with the control containing the 
ubiquitin E2-binding domain from ubiquitin's E1 indicating that this inhibition is specific for NEDD8 
E1-E2 interaction (Fig. 5.2d). 
In these studies we probed the two most common types of E3 ubiquitin ligases, HECT and RING, 
and three different E2 conjugating enzymes. In each case we found that the binding of E1 or E3 to an 
E2 is mutually exclusive. This result has important implications for the nature and processivity of 
ubiquitin and ubl modification. One prediction is that an efficient conjugation pathway requires an E3 
to have higher affinity for E2-ubiquitin or E2-ubl thioester, and indeed this has been observed for 
interactions between HsUbc2b and E3α (ref. 7), as well as Ubc4 with SCFβ-TRCP (ref. 8). 
Because an E2 cannot be reactivated by an E1 while it is bound to E3, polyubiquitination probably 
requires multiple E2-E3 binding events. Indeed, a study of the anaphase-promoting complex (APC), a 
multisubunit E3, indicated that multiple E2 molecules are needed to label substrate with multiple 
ubiquitins9. These previous results could reflect multiple E2 molecules binding the APC complex 
simultaneously, or they could indicate that E2s must be released from the APC before they can be 
reactivated with ubiquitin by an E1, consistent with our findings here. A recent study reports that 
multiple E2-E3 binding events are needed for Cdc34p-mediated polyubiquitination; however, they 
also propose a model that involves ubiquitin-conjugated E2 dissociating from its RING E3 before 
modifying the substrate with ubiquitin10. Our studies do not address this aspect of their model. Our 
studies do suggest a possible mechanism for the difference between mono- and polyubiquitinating 
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enzymes: a difference in turnover rates for substrate binding and E2 binding. E3s that release product 
quickly and turn over E2 slowly may catalyze monoubiquitination, whereas E3s that release product 
slowly and turn over E2 quickly may catalyze polyubiquitination. 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. An E2 binding to E1 and to a HECT E3 are mutually exclusive. (a) The change in 
fluorescence polarization of BODIPY-UbcH7 was measured upon titration of E6AP-HECT into 
UbcH7. (b) The initial rate of formation of UbcH7-[32P]-ubiquitin was measured at increasing 
concentrations of E6AP-HECT for the UbcH7-HECT interactions described. 
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Figure 5.2. E2s binding to E1s and to RING E3s is mutually exclusive. (a) Thioester formation 
between [32P]-ubiquitin and the ubiquitin E2 UbcH5B was monitored in the absence or presence of  
the E2-binding ubiquitin-fold domain (UFD) from ubiquitin’s or NEDD8’s E1.  (b) Chase reaction 
monitoring SCFβ-TRCP-mediated transfer of ubiquitin from the UbcH5b-[32P]-ubiquitin thioester to a 
peptide from β-catenin in the absence or presence of the E2-binding Ubiquitin-fold domain from 
ubiquitin’s or NEDD8’s E1.  (c) Thioester formation between [32P]-NEDD8 and the NEDD8 E2 
Ubc12 was monitored in the absence or presence of the E2-binding ubiquitin-fold domain from 
NEDD8’s or ubiquitin’s E1. (d) Chase reaction monitoring Cul1-Rbx1-mediated transfer of 32P-
NEDD8 from the Ubc12-[32P]-NEDD8 thioester to Cul1 in the absence or presence of the E2-binding 
Ubiquitin-fold domain from NEDD8’s or ubiquitin’s E1. 
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SUPPLEMENTARY METHODS 
 
Proteins for Biophysical and Biochemical Assays of E6AP(HECT)  
E6AP-HECT domain and UbcH7 single amino acid substitutions were generated using 
QuikChange site-directed mutagenesis kit (Stratagene).  All proteins were overexpressed in E.coli 
BL21(DE3) pLysS cells (Stratagene).  E.coli cultures were grown to an OD600 of 0.8 - 1.0 at 37 °C 
then induced with 0.33 mM IPTG for 6-8 hours at 25 °C.  Human UbcH7 was overexpressed with an 
N-terminal His6•tag from a pET vector then purified using metal chelating sepharose followed by 
cation exchange.  The HECT domain of human E6AP (residues 492-852) was overexpressed as a 
glutathione S-transferase (GST) fusion using pGEX-4T vector and was purified according to a 
previously described method1 with a single modification.  Following thrombin cleavage to remove the 
GST moiety, an irreversible thrombin inhibitor (PPACK dihydrochloride, EMD Biosciences) was 
added at a 5-fold molar excess.  Ubiquitin was overexpressed with an N-terminal His6•tag in a 
modified pET vector containing a protein kinase A (PKA) recognition sequence11.  Recombinant 
ubiquitin was purified using metal chelating sepharose followed by gel filtration.  Labeling of 
ubiquitin with 32P was carried out using a PKAce kit (EMD Biosciences) and the manufacturer's 
recommended protocol.  The labeling reaction was terminated with a 10-fold molar excess of protein 
kinase A inhibitor (PKI 6-22 Amide, EMD Biosciences).  UbcH7 and E6AP-HECT domain were 
dialyzed into the appropiate buffer then concentrated using centrifugal concentrators and quantitated 
according to the procedure given below.  Molar extinction coefficients for all proteins were predicted 
from the ExPASy ProtParam tool (www.expasy.org).  Quantification was carried out in 20 mM 
KH2PO4 and 6.0 M guanidinium hydrochloride pH 6.5 using the absorbance value at 280 nm.  Protein 
concentrations determined using molar extinction coefficients were confirmed using a Bradford 
assay. 
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RosettaDesign 
Mutations that enhance the affinity between UbcH7 and E6AP were identified using the 
RosettaDesign algorithm for protein design12 (rosettadesign.med.unc.edu).  To identify a small set of 
mutations that would increase binding affinity, a large set of independent simulations were 
performed.  In each simulation small clusters of residues at the interface were redesigned and ranked 
based on their effect on binding affinity and specificity and  K96S-UbcH7 and D641K-E6AP ranked 
highly in both categories. RosettaDesign attributes the enhanced affinity to the formation of an ideal 
hydrogen bond between Ser96-UbcH7 and Lys641-E6AP when they adopt their most favorable side 
chain conformations, while the wild type pair, lysine 96-UbcH7 and aspartate 641-E6AP, can only 
form a weak hydrogen bond when less favorable conformations are adopted. 
       
Fluorescence Polarization Assay 
The thiol-reactive fluorescent probe bodipy(507/545)-iodoacetamide (Molecular Probes) was 
conjugated to UbcH7 using the manufactures recommended protocol.  UbcH7 was concentrated to 
~100 µM then buffer exchanged into 50 mM Tris·Cl pH 7.5 and 1 mM TCEP using a PD10 desalting 
column.  The PD10 eluate was stirred for one hour at room temperature.  A 20 mM stock solution of 
bodipy(507/545-IA) suspended in dimethyl sulfoxide (DMSO) was diluted into the UbcH7 solution to 
a 10-fold molar excess and the conjugation reaction was allowed to proceed overnight, in the dark at 
4 °C.  The precipitate was pelleted and discarded then 5 mM β-mercaptoethanol (β-ME) was added to 
quench the reaction. The supernatant containing bodipy-UbcH7 was diluted and run over a PD10 
column to separate free probe from labeled protein.  Bodipy-UbcH7 was quantified using UV/Vis and 
a correction factor (Abs280 nm/Abs508 nm) of 0.03 was used to correct for the absorption of the 
conjugated probe at 280 nm.  In brief, the correction factor was determined by conjugating bodipy to 
a heptapeptide, NH2-KGACAGK-COOH (Sigma-Genosys), lacking absorbance at 280 nM then 
determining the ratio of absorbance at 280 nm and 508 nm of this bodipy conjugated peptide. 
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Fluorescence polarization assays were carried out on a Jobin Yvon Horiba Spex FluoroLog-3 
instrument (Jobin Yvon Inc.) performed in L-format with the excitation wavelength set at 508 nm and 
the emission wavelength set at 545 nm.  Bodipy-UbcH7 and HECT domain were dialyzed versus 20 
mM KH2PO4 pH 7.0, 150 mM NaCl and 5 mM β-ME.  Titrations were performed using a 3 x 3-mm 
quartz cuvette with a starting volume of 150 µL of wild type or mutant bodipy-UbcH7.  Bodipy 
labeled wild type or mutant UbcH7 was diluted to 100 or 500 nM and the excitation and emission slit 
widths adjusted between 3.0 and 4.2 nm to give a fluorescence intensity >100,000 counts per second.  
Wild type or mutant HECT domain was added in increasing volumes from a stock solution of 60 µM 
or 120 µM.  Three polarization readings consisting of 3 averaged measurements were collected for 
13-18 concentrations of HECT domain.  Data was averaged and analyzed using a model for single 
site binding according to Equation 1 which was incorporated into Equation 2 to account for the 
observed polarization.  
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where [E2:E3] is the concentration of bodipy-UbcH7 and HECT complex formed, [E2t] is the total 
concentration of bodipy-UbcH7, [E3t] is the concentration of HECT domain from E6AP, Kd is the 
dissociation constant for the interaction, Po is the polarization in the absence of HECT domain, Pmax is 
the maximum polarization observed when all bodipy-UbcH7 is bound to HECT domain, and Pobs is 
the measured polarization at a given concentration of HECT domain.  The data was fit according to 
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Equation 2 using nonlinear regression with SigmaPlot software to obtain fitted parameters for Kd, 
Pmax, and Po.  
 
Determination of kcat and Km for E1-mediated E2 transthiolation 
Determination of the kinetic parameters kcat and Km for the interaction between the human ubiquitin 
activating enzyme and UbcH7 was performed using slight modifications of a previously published 
method7.  The assays were carried out in 100 µL volumes containing 20 mM Tris·Cl pH 7.5, 50 mM 
NaCl, 10 mM MgCl2, 0.2 mM β-ME, 2 mM ATP, 10 mM creatine phosphate, 10 U/ml creatine 
kinase, 5 µM 32P-ubiquitin, 1 nM human ubiquitin E1 (Boston Biochem Inc.), and varying 
concentrations of UbcH7.  The E6AP-HECT domain active site point mutant C820A that lacks the 
ability to form a HECT~ubiquitin thiolester was used in experiments performed in the presence of 
high concentrations of HECT domain.  These kinetic assays were performed with 200 µM C820A-
HECT or 80 µM C820A-D641K-HECT.  Reaction components minus ubiquitin were allowed to 
equilibrate 10 minutes before initiating the reaction by the addition of 32P-ubiquitin.  Over the course 
of four minutes (before significant product accumulation), four aliquots of 20 µL were removed and 
quenched in 4X gel loading buffer lacking a reductant.  Proteins were separated by SDS-PAGE at 
room temperature and the gels were dried and exposed to a phosphor screen.  32P-ubiquitin bands 
were visualized by autoradiography using a phosphorimager and quantitation of data was performed 
using ImageQuant 5.0 software (Molecular Dynamics).  Background correction for each band was 
performed by subtracting the volume of counts from a box of equal area in the same gel lane. A lane 
containing only 32P-ubiquitin was included on the gel to convert the observed volume of counts to a 
concentration value.  The concentration of active E1 enzyme was determined from a lane lacking 
UbcH7.  Concentrations of UbcH7~32P-ubiquitin were measured and then plotted to determine the 
initial rates of thiolester formation.  Kinetic parameters kcat and Km were determined by fitting data to 
the Michaelis-Menton equation using nonlinear regression (SigmaPlot software).  For the assay 
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containing K96S-UbcH7 and C820A-D641K-HECT, the initial rates of E2~32P-ubiquitin formation 
remained linear over the range of K96S-UbcH7 concentrations tested.  To set a lower limit for Km (to 
95% confidence), a statistical F test was performed using χ2 values obtained from the residuals to the 
fit13. 
 
Determination of Ki for HECT inhibition of E1-mediated E2 transthiolation  
Reactions were carried out as described above except the E1 concentration was increased to 3 nM, 
the wild type and mutant UbcH7 concentration was fixed at 500 nM, and the wild type and mutant 
inactive HECT domain concentration varied from 0 to 100 µM.  Experiments were performed at E1 
concentrations below the Km of the E1-E2 interaction to ensure UbcH7 is not saturated with E1 
enzyme.  Single time points were taken at 2.5 minutes and data was analyzed as described above.  A 
modified Michaelis-Menton equation (Equation 3) was derived to model competitive inhibition by 
inactive HECT domain for the E1-E2 interaction.  Equation 3 incorporates an E2-E3 binding 
equilibrium (Equation 4) that is reflected in an apparent inhibition constant, Ki.  A baseline offset 
parameter, b, was also incorporated to account for error in background correction.  In Equation 3, the 
catalytic constant determined from the E1-E2 transthiolation assays in the absence of HECT domain 
was substituted and the data was fit to Ki, Km, and b using nonlinear regression (SigmaPlot software).   
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where [E2:E3*] is the concentration of E2 enzyme bound to catalytically inactive HECT domain from 
E6AP (C820A), [E3*t] is the total concentration of catalytically inactive HECT and Ki is the apparent 
inhibition constant. 
 
Biochemical Assays of RING E3s 
Proteins for biochemical assays of RING E3s were expressed and purified as described 
previously14-17.  Biochemical assays were performed in 10 µl in 50 mM Tris-HCl (pH 7.6-8.0), 50 
mM NaCl, 10 mM MgCl2, 5 mM ATP, 1-1.5 mM DTT, 0.3 U/ml inorganic pyrophosphatase, 0.3 
U/ml creatine phophatase, 5 mM creatine phosphate, 2 mg/ml ovalbumin, and NEDD8 or ubiquitin 
K>R (all lysines mutated to arginines) phosphorylated at the N-terminal PKA site (from pGEX2TK) 
with [γ-32P]ATP, at 18°C. Reactions were quenched with an equal volume of 2X SDS sample buffer, 
proteins were resolved by SDS-PAGE, dried and visualized by autoradiography. 
For ubiquitin pathway experiments, inhibition of E1-E2 transthiolation reactions used 5 nM UbE1, 
0.5 µM UbcH5b, 7 µM 32P-ubiquitin and 250 µM of the E2-binding domain from ubiquitin’s or 
NEDD8’s E1s (termed UbE1ufd  and NE1ufd, respectively) for 2 minutes.  Ubiquitin modification on 
the β-catenin peptide (sequence Ac- KAAVSHWQQQSYLDSGIHSGATTTAP-NH2) was examined 
using pulse-chase.  The pulse contained 18 nM APPBP1-UBA3, 0.9 µM UbcH5b and 2.5 µM 32P-
ubiquitin R7, and formation of the UbcH5b~32P-ubiquitin thioester complex was quenched after 
1hour with 230 µM cold ubiquitin and 90 mM EDTA.  The reactions were chased with 0.25 µM E3 
(neddylated split Cul1/Rbx1/βTCRP1/Skp1), 30 µM β-catenin peptide and 250 µM of either NE1UFD 
or UbE1UFD for 1 min. 
For NEDD8 pathway experiments, inhibition of E1-E2 transthiolation reactions used 1 nM 
APPBP1-UBA3, 0.2 µM Ubc12, 5 µM 32P-NEDD8 and 250 µM NE1ufd or UbE1ufd for 90 seconds.  
NEDD8 modification of Cul-1 was examined using pulse-chase.  The pulse contained 1 nM APPBP1-
UBA3, 0.2 µM Ubc12 and 1 µM 32P-NEDD8, and formation of the Ubc12~32P-NEDD8 thioester 
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complex was quenched after 7 min with 50 µM NEDD8, 50 mM EDTA and 0.8 mM Ubc12N26 
peptide.  The Ubc12N26 peptide was shown previously to efficiently inhibit Ubc12~NEDD8 thioester 
formation, with no effect on Rbx1-mediated transfer of NEDD8 to Cul16 (and DH and BAS, 
unpublished results).  The reactions were chased with 1 µM Rbx1-Cul1 and 250 µM NE1ufd or 
UbE1ufd for 1 min.  
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SUPPLEMENTARY DATA 
Figure 5.3.  Enhanced affinity UbcH7–E6AP-HECT pair inhibits E1-mediated UbcH7 
transthiolation at lower E6AP-HECT concentrations.  UbcH7~[32P]-ubiquitin bands were 
quantitated from kinetic inhibition assays performed in Figure 5.1b to determine initial rates 
of UbcH7~[32P]-ubiquitin formation. Initial velocity data were fit to a modified Michaelis-
Menton scheme to determine an apparent inhibition constant, Ki, for the UbcH7–E6AP-
HECT interactions. Kinetic parameters kcat and Km for the E1–UbcH7 interaction were 
determined from independent experiments (see Supplementary Data, Fig. 5.4) and used in 
the fitting process. The apparent inhibition constants are consistent with the dissociation 
constants determined using the fluorescence polarization assay. 
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Figure 5.4. Kinetics of E1-mediated UbcH7~[32P]-ubiquitin formation in the presence and absence of 
high concentrations of E6AP-HECT. (a) In vitro ubiquitination reactions were performed with 1 nM 
E1, 5 mM [32P]-Ubiquitin, 2 mM ATP and an ATP regenerating system. Assays were performed at 
varying E2 concentrations for UbcH7 WT in absence (closed circles) and presence of 200 mM 
C820A-HECT (closed triangles), and for UbcH7 K96S in absence (open circles) and presence of 80 
mM C820A D641K-HECT (open triangles). UbcH7~[32P]-ubiquitin bands were resolved by SDS-
PAGE and quantified to determine the initial velocities of UbcH7~[32P]-ubiquitin formation. Initial 
velocities were fit to the Michaelis-Menton equation to determine the kinetic parameters kcat and Km. 
(b) Table of fitted kinetic parameters kcat and Km.  Uncertainties in kinetic parameters are reported as 
standard errors. 
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In our studies on the UbcH7–E6AP interface we found 10 side-chains that were important 
for maintaining a high affinity interaction.  Eight of these side-chains are cluster together at 
the center of the interface and form a hydrophobic interface core.  The single residue that 
contributes most to binding is F63-UbcH7 which provides about 3 kcal/mol to the free 
energy of binding.  This in fact is the primary specificity determining residue for HECT E3s 
because all E2s known to function with HECT E3s possess a phenylalanine at this position.  
We found three additional UbcH7–E6AP specificity determining residues at S4, K96, and 
K100 of UbcH7.  Though not determined at the time, the role of K96 and K100 in E6AP 
specificity could be deduced from a multiple sequence alignment and the UbcH7–E6AP 
crystal structure.  We stumbled upon S4 in attempt to reengineer UbcH5b to interact with 
E6AP with UbcH7-like affinity.  The S4A-UbcH7 mutant was not largely unfavorable for 
E6AP binding so we had little reason to expect it was dictating specificity.  It was the L3S-
UbcH5b mutant that ultimately led to generating a high affinity UbcH5b–E6AP interaction.  
An interesting finding from these studies was that the S94K-UbcH5b protein was unable 
induce a tighter association with E6AP; this suggests that loop 7 in UbcH7 has an optimal 
orientation for interacting with E6AP. 
Our results assessing E2–HECT specificity agrees with previous findings.  The E6AP 
protein selectively interacts with the E2-L subfamily while Nedd4L prefers the E2-E and 
UBC4/5 subfamilies.  The basis for Nedd4L selectivity may stem in part from a hydrogen 
bond interaction not present in E6AP (T58-UbcH5b–D778-Nedd4L).  Nedd4L in part disfavors 
binding UbcH7 because the K96 side-chain sterically clashes with W762 of Nedd4L.  More mutations 
to both Nedd4L and UbcH7 will be tested address some of these interpretations.  Smurf2 and 
Huwe1 were incapable of forming high affinity interactions with E2s.  This result for Smurf2 
is consistent with previous finding that it possesses side-chains that disfavor E2-binding.  
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Indeed Smurf2 requires a tertiary protein capable of recruiting and E2 for increased activity.  
The Huwe1 protein has many additional domains that may facilitate interactions with 
tertiary, E2-recruiting proteins.  Less is know about E2–Huwe1 specificity but our results 
suggest it functions in a manner similar to Smurf2.  Both Huwe1 and Smuf2 express well in 
E.coli and are very soluble so an interesting project in my view would be attempting to 
enhance an E2–Huwe1 or E2–Smurf2 interaction.  I have retrieved and subcloned many other 
HECT domains that have not yet been characterized.  These include the five yeast HECT 
domains as well as human Itch, WWP1, and Herc5 (an ISG15 HECT E3).  In humans there 
are ~27 HECT E3s and ~33 E2s so ~900 interactions of which I have characterized 60 (~ 
7%). 
Manipulating UbcH7–E6AP interactions led to some very interesting findings.  We found 
that just three mutations to these proteins were needed to gain ~1000-fold increase in affinity.  
I was able to create UbcH7–E6AP pairs containing F63Y and F63H mutations that bound 
with wild-type or tighter affinity.  These could prove useful in the cell because no E2 with a 
Tyr or His at this position has been shown to function with a HECT E3.  The K96S–D641K 
pair proved quite useful in answering an important question pertaining to the mechanism of 
poly-ubiquitination.  In collaboration with Brenda Schulman’s group we were able to show 
that E2s cannot simultaneously bind E1 and E3 enzymes.  This implies that for poly-
ubiquitination the E2 must release from the E3 to become recharged with ubiquitin.  This 
study also suggests that nanomolar E2–E3 binding affinities may have adverse effects inside 
the cell.  Other studies which are ongoing aim to better assess whether an increase in E2–E3 
binding affinity directly correlates to an increase in E2–E3 activity.  This has been a 
challenging question to answer because ubiquitin transfer from E1 to E2 is slow while E2 
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transfer to E3 is very fast.  The E1 enzyme is currently being purchased from Boston 
Biochem so creating conditions where E2-E3 transfer is the rate-limiting step has proven 
difficult.  The work conducted in this dissertation has shed insights into many aspects of the 
ubiquitin pathway and will certainly aid efforts to manipulate E2–E3 interactions and dissect 
the ubiquitin pathway.     
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APPENDIX I: 
PHYLOGENETIC TREE OF HUMAN E2s 
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APPENDIX II: 
PHYLOGENETIC TREE OF HUMAN HECT E3s 
 
